U.S. patent application number 16/853635 was filed with the patent office on 2020-08-06 for liposomes comprising polymer-conjugated lipids and related uses.
The applicant listed for this patent is Yissum Research Development Company of the University of Jerusalem Ltd.. Invention is credited to Saul YEDGAR.
Application Number | 20200246265 16/853635 |
Document ID | / |
Family ID | 1000004766168 |
Filed Date | 2020-08-06 |
View All Diagrams
United States Patent
Application |
20200246265 |
Kind Code |
A1 |
YEDGAR; Saul |
August 6, 2020 |
LIPOSOMES COMPRISING POLYMER-CONJUGATED LIPIDS AND RELATED USES
Abstract
The present invention provides liposomes comprising a lipid
bilayer and a polymer-conjugated lipid, wherein said
polymer-conjugated lipid is incorporated into said lipid bilayer.
The present invention also provides methods of producing the
liposomes as well as a method of delivering a nucleic acid to a
subject comprising the step of administering said nucleic acid
encapsulated in a mixed liposome, a method for performing
diagnostic imaging in a subject, comprising the step of
administering a diagnost-ic agent encapsulated in a mixed liposome,
and methods for treating, inhibiting, or suppressing a pathological
condition in a subject comprising administering to said subject a
mixed liposome.
Inventors: |
YEDGAR; Saul; (Jerusalem,
IL) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Yissum Research Development Company of the University of Jerusalem
Ltd. |
Jerusalem |
|
IL |
|
|
Family ID: |
1000004766168 |
Appl. No.: |
16/853635 |
Filed: |
April 20, 2020 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16246920 |
Jan 14, 2019 |
10624851 |
|
|
16853635 |
|
|
|
|
14115869 |
Feb 7, 2014 |
10179106 |
|
|
PCT/IL12/50168 |
May 10, 2012 |
|
|
|
16246920 |
|
|
|
|
61485192 |
May 12, 2011 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 47/6911 20170801;
A61K 9/1271 20130101; A61K 31/713 20130101; A61K 9/127
20130101 |
International
Class: |
A61K 9/127 20060101
A61K009/127; A61K 47/69 20060101 A61K047/69; A61K 31/713 20060101
A61K031/713 |
Claims
1. A liposome comprising a lipid bilayer and a polymer-conjugated
lipid, wherein said polymer-conjugated lipid is incorporated into
said lipid bilayer.
2. The liposome of claim 1, wherein said liposome is a
nanoliposome.
3-5. (canceled)
6. The liposome of claim 1, wherein said polymer-conjugated lipid
comprises two or more lipids conjugated to a single polymer.
7. The liposome of claim 6, wherein the ratio of lipids to polymer
units in said polymerconjugated lipid is between 2:4 and
2:2000.
8. The liposome of claim 1, wherein said polymer is Haemaccel.
9. (canceled)
10. The liposome of claim 1, wherein said polymer is a
polysaccharide.
11. The liposome of claim 10, wherein said polysaccharide is a
glycosaminoglycan, chitosan, alginic acid, hetastarch and
dextran.
12. The liposome of claim 11, wherein said polysaccharide is a
glycosaminoglycan seletcted from the groupd consisting of
hyaluronic acid, chondroitin, Keratan, dermatan and heparin.
13-17. (canceled)
18. The liposome of claim 1, wherein said polysaccharide is
conjugated to said lipid via a glutaryl linker.
19-22. (canceled)
23. The liposome of claim 1, wherein said lipid is a
phospholipid.
24. The liposome of claim 23, wherein said phospholipid is
phosphatidylethanolamine.
25. (canceled)
26. The liposome of claim, wherein said further comprises a
polyethylene glycol (PEG)-conjugated lipid.
27-63. (canceled)
64. A method of producing a mixed liposome comprising the step of
conjugating a lipid with a polymer to form a polymer-conjugated
lipid and contacting said polymer-conjugated lipid with a liposome
to produce a mixed liposome.
65. The method of claim 64, further comprising the step of
isolating said polymer-conjugated lipid prior to said contacting
step.
66-98. (canceled)
99. A method of delivering a nucleic acid to a subject comprising
the step of administering said nucleic acid encapsulated in a
liposome of claim 1 to said subject.
100. (canceled)
101. A method for performing diagnostic imaging in a subject,
comprising the step of administering a diagnostic agent
encapsulated in a liposome of claim 1 to said subject and imaging
said patient.
102. A method for treating, inhibiting or suppressing a
pathological condition in a subject, comprising administering to
said subject a liposome of claim 1.
103. The method of claim 102, wherein said pathological condition
is selected from the group consisting of a cancer, an infection,
obstructive respiratory disease, a dermatological condition, cystic
fibrosis, eye disorder, inflammatory bowel disease and nervous
system disorder.
104-114. (canceled)
115. The method of claim 102, wherein said liposome further
comprises a bioactive agent for treating said pathological
condition.
116-118. (canceled)
119. The method of claim 102, wherein said drug is administered
orally, intravenously, intranasally intraocularly, intramuscularly,
subcutaneously or topically.
120-123. (canceled)
Description
FIELD OF THE INVENTION
[0001] The present invention provides liposomes comprising a lipid
bilayer and a polymer-conjugated lipid, wherein said
polymer-conjugated lipid is incorporated into said lipid bilayer.
The present invention also provides methods of producing the
liposomes as well as a method of delivering a nucleic acid to a
subject comprising the step of administering said nucleic acid
encapsulated in a mixed liposome, a method for performing
diagnostic imaging in a subject, comprising the step of
administering a diagnostic agent encapsulated in a mixed liposome,
and methods for treating, inhibiting, or suppressing a pathological
condition in a subject comprising administering to said subject a
mixed liposome.
BACKGROUND OF THE INVENTION
[0002] The use of drug delivery systems providing both slow release
of drugs and specific targeting of drugs to the desired affected
organs/systems in order to reduce systemic distribution and
exposure of non-target organs has long been sought. One promising
candidate has been phospholipid (PL) liposomes and their
derivatives. Liposomes are small, spherical vesicles composed of
phospholipids and consist of one or more lipid bilayers enclosing
an aqueous interior. Liposomes can encapsulate both hydrophilic
drugs (in the aqueous interior) and lipophilic drugs (in the lipid
bilayer), and are thus highly suitable for drug delivery.
[0003] Phospholipid liposomes can serve as sustained-release or
controlled-release drug depots, thus contributing to improvement in
drug efficacy and allowing reduction in the frequency of dosing. By
providing protection of both the entrapped drug and the biological
environment, liposomes reduce the risks of drug inactivation and
drug degradation. Since the pharmacokinetics of free drug release
from the particles are different from directly-administered free
drug, these carriers can be used to reduce toxicity and undesirable
side effects.
[0004] Phospholipid liposomes can be prepared at a wide range of
sizes (50-500 nm). Since in inflamed tissues, the intercellular
space is enlarged from the normal distance of 50 nm to 100 nm,
drug-carrying liposomes smaller than 100 nm are suitable for
selective delivery of drugs to target systems.
[0005] Despite the advantages offered, there are some difficulties
associated with using drug encapsulating liposomes. For example,
liposomes have limited targeting abilities, limited retention and
stability in circulation, potential toxicity upon chronic
administration, and the inability to extravasate.
[0006] To circumvent the drawbacks of known nanoliposomes, we have
used polymer-conjugated lipids (Po-Ls) for the formation of mixed
lipid/Po-L nanoliposomes.
SUMMARY OF THE INVENTION
[0007] In one embodiment, the present invention provides a liposome
comprising a lipid bilayer and a polymer-conjugated lipid, wherein
said polymer-conjugated lipid is incorporated into said lipid
bilayer.
[0008] In another embodiment, the present invention provides a
liposome comprising a lipid bilayer and a glycosaminoglycan
(GAG)-conjugated lipid, wherein said polymer-conjugated lipid is
incorporated into said lipid bilayer.
[0009] In another embodiment, the present invention provides a
liposome comprising a lipid bilayer and a polymer-conjugated lipid,
wherein said polymer-conjugated lipid is incorporated into said
lipid bilayer and wherein said polymer is not a
glycosaminoglycan.
[0010] In another embodiment, the present invention provides a
method of producing a mixed liposome comprising the step of
conjugating a lipid with a polymer to form a polymer-conjugated
lipid and contacting said polymer-conjugated lipid with a liposome
to produce a mixed liposome.
[0011] In another embodiment, the present invention provides a
mixed liposome produced by the method comprising the step of
conjugating a lipid with a polymer to form a polymer-conjugated
lipid and contacting said polymer-conjugated lipid with a liposome
to produce a mixed liposome.
[0012] In another embodiment, the present invention provides a
composition comprising a liposome comprising a lipid bilayer and a
polymer-conjugated lipid, wherein said polymer-conjugated lipid is
incorporated into said lipid bilayer.
[0013] In another embodiment, the present invention provides a
composition comprising a liposome comprising a lipid bilayer and a
glycosaminoglycan (GAG)-conjugated lipid, wherein said
polymer-conjugated lipid is incorporated into said lipid
bilayer.
[0014] In another embodiment, the present invention provides a
composition comprising a liposome comprising a lipid bilayer and a
polymer-conjugated lipid, wherein said polymer-conjugated lipid is
incorporated into said lipid bilayer and wherein said polymer is
not a glycosaminoglycan.
[0015] In another embodiment, the present invention provides a drug
delivery system comprising a liposome comprising a lipid bilayer
and a polymer-conjugated lipid, wherein said polymer-conjugated
lipid is incorporated into said lipid bilayer.
[0016] In another embodiment, the present invention provides a
method of delivering a nucleic acid to a subject comprising the
step of administering said nucleic acid encapsulated in a liposome
comprising a lipid bilayer and a polymer-conjugated lipid, wherein
said polymer-conjugated lipid is incorporated into said lipid
bilayer to said subject.
[0017] In another embodiment, the present invention provides a
method for performing diagnostic imaging in a subject, comprising
the step of administering a diagnostic agent encapsulated in a
liposome comprising a lipid bilayer and a polymer-conjugated lipid,
wherein said polymer-conjugated lipid is incorporated into said
lipid bilayer to said subject and imaging said patient.
[0018] In another embodiment, the present invention provides a
method for treating, inhibiting, or suppressing a pathological
condition in a subject, comprising administering to said subject a
liposome comprising a lipid bilayer and a polymer-conjugated lipid,
wherein said polymer-conjugated lipid is incorporated into said
lipid bilayer.
BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The subject matter regarded as the invention is particularly
pointed out and distinctly claimed in the concluding portion of the
specification. The invention, however, may best be understood by
reference to the following detailed description when read with the
accompanying drawings.
[0020] FIG. 1: Models representing how variations in
polymer-conjugated lipid (Po-L)/liposome ratio and polymer size
affect structure and function of Po-L/liposomes: (a) Mushroom;
obtained at lower Po-L/liposome ratio. (b) Brush, obtained at
higher Po-L/liposome ratio (c) Surface coating, obtained with high
MW HA (or other GAGs).
[0021] FIG. 2: Effect of HyPE on the stability of liposomes
composed of EggPC:Chol:HyPE, expressed by the change in the
Additive Packing Parameter (PP) of the liposomes: The figure shows
the PP as a function of mole percent of PE conjugated to HyPE in
the liposomes. Optimal stability is obtained when PP is close to
1.0 (but not higher than 1). The vertical lines show the HyPE
concentrations that increase the liposome stability. EggPC=egg
phosphatidyl-choline; Chol=Cholesterol; HyPE=Hyaluronic acid
(HA)-conjugated phosphatidyl-ethanolamine (PE).
[0022] FIG. 3: Size stability of liposomes with different
polymer-conjugated lipids (Po-Ls): Liposomes with or without the
indicated Po-L were incubated at 55.degree. C. for 17 days, and the
change in their size was monitored using dynamic light scattering.
The diagram shows the sizes (nm) at day 1 and 17. DMPC=dimyristoyl
phosphatidyl-choline; HyPE=HyPE=Hyaluronic acid (HA)-conjugated
Phosphatidyl-ethanolamine (PE); Dex (5)-PE=Dextran (MW
5K)-conjugated PE; Dex(40)=Dextran (MW 40K)-conjugated PE;
Heta-PE=Hetastarch (hydroxyethylstarch)-conjugated PE;
Hem-PE=Hemaccel (Polygeline)-conjugated PE.
[0023] FIG. 4: Po-L inhibits liposome decomposition by external
PLA.sub.2. Liposomes composed of di-oleoyl-phosphatidyl-choline
(DOPC) and PC labeled with C.sub.6-NBD (a fluorescent fatty acid)
at carbon 2, with or without HyPE, were interacted with external
phospholipase A2 (PLA2). The hydrolysis of liposomal phospholipids
was determined by the release of the fluorescence intensity of
C6-NBD-fatty acid PC release by the PLA2 action. The figure depicts
the time required to hydrolyze 5% of the liposomal C6-NBD-PC
(representing the total liposomal phospholipids).
[0024] FIG. 5: Stability of liposomes examined by retention of
encapsulated drug (Inulin fluorescein=InFl): InFl-containing
Liposomes composed of dimyristoyl phosphatidyl-choline (DMPC) with
or without Pol-PLI (HyPE) were incubated at 37.degree. C. in blood
plasma, and the In-Fl released to the extra-liposomal medium was
monitored for 6 days.
[0025] FIG. 6: Effect of Pol-PLI on stability of liposomes in rat
blood (in vivo): InFl-containing Liposomes were injected to the
tail vein of rats, and the retention of drug in the circulation was
monitored for 28 hour, by determination of the drug level in blood
samples taken 5 minutes and 28 hours after injection, and expressed
as percent of the initial, injected InFl amount. The figure shows
that the addition of Hem-PE to the liposomes markedly slowed down
the drug release from the liposomes.
DETAILED DESCRIPTION OF THE PRESENT INVENTION
[0026] A nanoliposome, or submicron bilayer lipid vesicle, is a
technology for the encapsulation and delivery of bioactive agents.
The list of bioactive material that can be incorporated to
nanoliposomes is immense, ranging from pharmaceuticals to cosmetics
and nutraceuticals. Because of their biocompatibility and
biodegradability, along with their nanosize, nanoliposomes have
potential applications in a vast range of fields, including
nanotherapy (e.g. diagnosis, cancer therapy, gene delivery),
cosmetics, food technology and agriculture. Nanoliposomes are able
to enhance the performance of bioactive agents by improving their
solubility and bioavailability, in vitro and in vivo stability, as
well as preventing their unwanted interactions with other
molecules. Another advantage of nanoliposomes is cell-specific
targeting, which is a prerequisite to attain drug concentrations
required for optimum therapeutic efficacy in the target site while
minimizing adverse effects on healthy cells and tissues.
Polymer-Conjugated Lipid (Pol-L) Liposomes
[0027] In one embodiment, the present invention provides a liposome
comprising a lipid bilayer and a polymer-conjugated lipid, wherein
said polymer-conjugated lipid is incorporated into said lipid
bilayer.
[0028] In one embodiment, the liposome is made from a first lipid
while the lipid of the polymer-conjugated lipid(s) is made from a
second lipid which is a different lipid from said first lipid. For
example, and in one embodiment, the liposomes may be made using
phosphatidylcholine, with or without cholesterol, while the
conjugate may be made using phosphatidylethanolamine. In one
embodiment, the polymer is a polysaccharide. In one embodiment, the
polysaccharide is a glycosaminoglycan.
[0029] In one embodiment, said polymer is conjugated to said lipid
via a covalent bond. In one embodiment, said polymer is
cross-linked to said lipid.
[0030] In one embodiment, the present invention provides a liposome
comprising two or more polymer-conjugated lipids, wherein said
polymer-conjugated lipid comprises two or more lipids conjugated to
a single polymer.
[0031] In one embodiment, the polymer-conjugated lipid is an
inhibitor of phospholipase A2, or in another embodiment, the
polymer-conjugated lipid inhibits the activity, function, or
expression of phopholipase A2.
[0032] In one embodiment, the polymer is alginic acid. In one
embodiment, the alginic acid is low molecular weight alginic acid.
In another embodiment, the alginic acid is truncated.
[0033] In another embodiment, the present invention provides a
liposome comprising a lipid bilayer and a glycosaminoglycan
(GAG)-conjugated lipid, wherein said polymer-conjugated lipid is
incorporated into said lipid bilayer.
[0034] In another embodiment, the present invention provides a
liposome comprising two or more glycosaminoglycan (GAG)-conjugated
lipids, wherein said GAG-conjugated lipid comprises two or more
lipids conjugated to a single GAG.
[0035] In another embodiment, the present invention provides a
liposome comprising two or more glycosaminoglycan (GAG)-conjugated
phospholipids, wherein said GAG-conjugated phospholipid comprises
two or more phospholipids conjugated to a single GAG.
[0036] In one embodiment, the GAG is hyaluronic acid. In one
embodiment, the hyaluronic acid is low molecular weight hyaluronic
acid. In another embodiment, the hyaluronic acid is truncated.
[0037] In another embodiment, the present invention provides a
liposome comprising two or more low molecular weight hyaluronic
acid-conjugated phosphatidylethanolamine, wherein said low
molecular weight hyaluronic acid-conjugated
phosphatidylethanolamine comprises two or more hyaluronic
acid-conjugated phosphatidylethanolamines conjugated to a single
hyaluronic acid.
[0038] In another embodiment, the present invention provides a
liposome comprising a lipid bilayer and a polymer-conjugated lipid,
wherein said polymer-conjugated lipid is incorporated into said
lipid bilayer and wherein said polymer is not a
glycosaminoglycan.
[0039] In another embodiment, the present invention provides a
liposome comprising a polymer-conjugated lipid, wherein said
polymer is not a glycosaminoglycan. In another embodiment, the
present invention provides a liposome comprising a
polymer-conjugated lipid, wherein said polymer is not hyaluronic
acid.
[0040] In one embodiment, the polymer is a polysaccharide. In one
embodiment, the lipid is a phospholipid. In one embodiment, the
liposome comprises a lipid bilayer. In one embodiment, the
polymer-conjugated lipid is incorporated into the lipid bilayer of
the liposome. In one embodiment, the liposome is a modified
liposome.
[0041] In one embodiment, the liposome is a nanoliposome. In one
embodiment, the liposome is less than 100 nm in diameter. In
another embodiment, the liposome is less than 150 nm in diameter.
In another embodiment, the liposome is less than 75 nm in diameter.
In another embodiment, the liposome is less than 50 nm in diameter.
In another embodiment, the liposome is 1-100 nm in diameter. In
another embodiment, the liposome is 20-100 nm in diameter. In
another embodiment, the liposome is 50-100 nm in diameter. In
another embodiment, the liposome is 50-150 nm in diameter. In
another embodiment, the liposome is 20-150 nm in diameter. In
another embodiment, the liposome is 10-50 nm in diameter.
[0042] In one embodiment, the liposome comprises a lipid bilayer
and said polymer-conjugated lipid is incorporated into both the
inner and outer leaflets of said lipid bilayer. In another
embodiment, the liposome comprises a lipid bilayer and said
polymer-conjugated lipid is incorporated only into the outer
leaflet of said lipid bilayer. In another embodiment, the liposome
comprises a lipid bilayer and said polymer-conjugated lipid is
incorporated only into the inner leaflet of said lipid bilayer.
[0043] In another embodiment, Po-L liposomes of the present
invention provide liposomes that are unusually stable. In one
embodiment, Po-L liposomes of the present invention are inserted
symmetrically to both the inner and outer leaflets of the liposome,
i.e., having the polymer at both liposome surfaces, which in one
embodiment, increases the liposome stability compared to the
stability of the liposome when a small polymer is inserted only on
the outer surface (leaflet) of the liposome. In one embodiment,
insertion of a large polymer to only the outer liposome surface
creates excessive asymmetry in the liposome and compromises the
liposome stability.
[0044] In another embodiment, the present invention provides a
modified liposome comprising a lipid bilayer, wherein said liposome
comprises two or more polysaccharide-conjugated phospholipids
(PoS-PLs) incorporated into said lipid bilayer.
[0045] In one embodiment, a liposome of the present invention is a
modified liposome in that the liposome incorporates a
polymer-conjugated lipid as described herein into its lipid
bilayer, which in one embodiment, is comprised of a different lipid
that the lipid of the polymer-conjugated lipid.
[0046] In one embodiment, a modified liposome of the present
invention is referred to as a mixed liposome.
[0047] In another embodiment, the present invention provides a
modified liposome comprising a lipid bilayer, wherein said liposome
comprises a polysaccharide-conjugated phospholipid (PoS-PL)
incorporated into said lipid bilayer, wherein said polysaccharide
is a glycosaminoglycan.
[0048] In another embodiment, the present invention provides a
modified liposome comprising a lipid bilayer, wherein said liposome
comprises a polysaccharide-conjugated phospholipid (PoS-PL)
incorporated into said lipid bilayer, wherein said polysaccharide
is a low molecular weight glycosaminoglycan.
[0049] In another embodiment, the present invention provides a
modified liposome comprising a lipid bilayer, wherein said liposome
comprises a polysaccharide-conjugated phospholipid (PoS-PL)
incorporated into said lipid bilayer, wherein said polysaccharide
is not a glycosaminoglycan.
[0050] In one embodiment, the present invention provides liposomes
comprising polymer-conjugated lipids. In another embodiment, the
present invention provides micelles comprising polymer-conjugated
lipids. In another embodiment, the present invention provides
nanoliposomes comprising polymer-conjugated lipids. In another
embodiment, the present invention provides archaeosomes comprising
polymer-conjugated lipids. In another embodiment, the present
invention provides immunoliposomes comprising polymer-conjugated
lipids. In another embodiment, the present invention provides
virosomes comprising polymer-conjugated lipids. In another
embodiment, the present invention provides ultradeformable vesicles
comprising polymer-conjugated lipids. In another embodiment, the
present invention provides stealth liposomes comprising
polymer-conjugated lipids. In one embodiment, the polymer is a
polysaccharide.
[0051] In one embodiment, the polymer-conjugated lipid comprises
two or more lipids conjugated to a single polymer.
[0052] In one embodiment, the ratio of lipids to repeating polymer
units in said polymer-conjugated lipid is between 1:2 and 1:1000.
In another embodiment, the ratio of lipids to repeating polymer
units in said polymer-conjugated lipid is between 2:4 and 2:2000.
In another embodiment, the ratio of lipids to repeating polymer
units in said polymer-conjugated lipid is between 1:28 and 1:62. In
another embodiment, the ratio of lipids to repeating polymer units
in said polymer-conjugated lipid is between 1:100 and 1:500. In
another embodiment, the ratio of lipids to repeating polymer units
in said polymer-conjugated lipid is between 1:25 and 1:35. In
another embodiment, the ratio of lipids to repeating polymer units
in said polymer-conjugated lipid is between 1:55 and 1:65. In
another embodiment, the ratio of lipids to repeating polymer units
in said polymer-conjugated lipid is between 1:20 and 1:70. In
another embodiment, the ratio of lipids to repeating polymer units
in said polymer-conjugated lipid is between 1:10 and 1:100. In
another embodiment, the ratio of lipids to repeating polymer units
in said polymer-conjugated lipid is between 1:50 and 1:500. In
another embodiment, the ratio of lipids to repeating polymer units
in said polymer-conjugated lipid is under 1:100.
[0053] In one embodiment, the ratio of repeating polymer units to
lipids in said polymer-conjugated lipid is between 20 and 70. In
another embodiment, the ratio of repeating polymer units to lipids
in said polymer-conjugated lipid is between 28 and 62. In another
embodiment, the ratio of repeating polymer units to lipids in said
polymer-conjugated lipid is between 10 and 80. In another
embodiment, the ratio of repeating polymer units to lipids in said
polymer-conjugated lipid is approximately 30. In another
embodiment, the ratio of repeating polymer units to lipids in said
polymer-conjugated lipid is 28. In another embodiment, the ratio of
repeating polymer units to lipids in said polymer-conjugated lipid
is 25-30. In another embodiment, the ratio of repeating polymer
units to lipids in said polymer-conjugated lipid is 20-35. In
another embodiment, the ratio of repeating polymer units to lipids
in said polymer-conjugated lipid is 15-40. In another embodiment,
the ratio of repeating polymer units to lipids in said
polymer-conjugated lipid is approximately 60. In another
embodiment, the ratio of repeating polymer units to lipids in said
polymer-conjugated lipid is 62. In another embodiment, the ratio of
repeating polymer units to lipids in said polymer-conjugated lipid
is 60-65. In another embodiment, the ratio of repeating polymer
units to lipids in said polymer-conjugated lipid is 55-70. In
another embodiment, the ratio of repeating polymer units to lipids
in said polymer-conjugated lipid is 50-75. In one embodiment, the
number or range is approximately the number or range described
hereinabove. In one embodiment, the ratio of repeating polymer
units to lipids is the molar ratio.
[0054] In one embodiment, the polymer is a polysaccharide, which in
one embodiment, is a low molecular weight polysaccharide. In one
embodiment, a repeating polymer unit is a repeating disaccharide
unit. In another embodiment, the polymer is not a polysaccharide,
which in one embodiment, is Haemaccel.
[0055] In one embodiment, the molecular weight of said
polysaccharide is between 5 and 20 kD. In one embodiment, the
PoS-PL is prepared by reacting a polysaccharide with a phospholipid
in a mass.sub.PL to mass.sub.GAG ratio from about 1:50 to about
1:1, respectively. In another embodiment, said mass.sub.PL to
mass.sub.GAG ratio is from about 1:50 to about 1:10. In another
embodiment, said mass.sub.PL to mass.sub.GAG ratio is from about
1:40 to about 1:1. In another embodiment, said mass.sub.PL to
mass.sub.GAG ratio is from about 1:10 to about 1:40.
[0056] In another embodiment, said mass.sub.PL to mass.sub.GAG
ratio is about 1:25. In another embodiment, said mass.sub.PL to
mass.sub.GAG ratio is about 0.5:15. In another embodiment, said
mass.sub.PL to mass.sub.GAG ratio is about 1:15. In another
embodiment, said mass.sub.PL to mass.sub.GAG ratio is about 2:15.
In another embodiment, said mass.sub.PL to mass.sub.GAG ratio is
about 5:15.
[0057] In another embodiment, the polydispersity of said GAG is
from about 1:50 up to 50:50. In another embodiment, the
polydispersity of said GAG is from about 1 to 1.75. In another
embodiment, the polydispersity of said GAG is from about 1.25 to
1.5.
[0058] In one embodiment, the lipid-polymer conjugate of the
present invention comprises a low molecular weight polysaccharide
wherein the average molecular weight of said polysaccharide is
between 5 kD and 90 kd. In another embodiment, the average
molecular weight of said polysaccharide is between 5 kD and 60 kD.
In another embodiment, the average molecular weight of said
polysaccharide is between 5 kD and 40 kD. In another embodiment,
the average molecular weight of said polysaccharide is between 5 kD
and 15 kD. In another embodiment, the average molecular weight of
said polysaccharide is between 5 kD and 20 kD.
[0059] In another embodiment, the average molecular weight of said
polysaccharide is between 10 kD and 30 kD. In another embodiment,
the average molecular weight of said polysaccharide is between 10
kD and 50 kD. In another embodiment, the average molecular weight
of said polysaccharide is greater than 10 kD.
[0060] In one embodiment, the polysaccharide is a glycosaminoglycan
(GAG). In one embodiment, the polymer-conjugated lipid is a
glycosaminoglycan-conjugated phospholipid. In one embodiment, a
glycosaminoglycan is a mucopolysaccharide. In one embodiment, a
glycosaminoglycan is a long chain composed of repeating
disaccharide units (aminosugar-acidic sugar repeating units). In
one embodiment, the amino sugar is glucosamine or galactosamine. In
one embodiment, the amino sugar is sulfated. In one embodiment, the
acidic sugar is D-glucuronic acid or L-iduronic acid.
[0061] In one embodiment, a glycosaminoglycan encompasses salts and
free acids of glycosaminoglycan as well as glycosaminoglycans that
have been chemically altered, yet retain their function. These
modifications comprise esterification, sulfation, polysulfation,
and methylation. For example, hyaluronate salts comprise sodium
hyaluronate, potassium hyaluronate, magnesium hyaluronate, and
calcium hyaluronate.
[0062] In one embodiment, a glycosaminoglycan may be chemically
modified to contain more sulfur groups than in their initially
extracted form. In another embodiment, a glycosaminoglycan may be
partially or completely synthesized and may be of either plant or
animal origin.
[0063] In one embodiment, glycosaminoglycans are obtained from
natural sources. In one embodiment, natural sources of
glycosaminoglycans include both plant and animal sources, i.e.,
beechwood trees and forms of animal cartilage, including shark
cartilage, bovine trachea, whale septum, porcine nostrils, and
mollusks such as Perna canaliculus and sea cucumber. In another
embodiment, glycosaminoglycans for use in the present invention are
recombinant glycosaminoglycans.
[0064] In one embodiment, glycosaminoglycans are then truncated to
approximately 10-30 kD for use in the compositions and methods of
the present invention.
[0065] In one embodiment of the invention, the glycosaminoglycan
may be, inter alia, hyaluronic acid, heparin, heparan sulfate,
chondrotin sulfate, keratin, keratan sulfate, dermatan sulfate, or
a derivative thereof.
[0066] In one embodiment, the GAG is hyaluronic acid. In one
embodiment, the hyaluronic acid is low molecular weight hyaluronic
acid, truncated hyaluronic acid, or a combination thereof. In one
embodiment, the low molecular weight hyaluronic acid has an average
molecular weight of approximately 10-50 kD.
[0067] In one embodiment, polymers of the present invention bind
covalently to lipids of the present invention. In one embodiment,
high molecular weight GAGs, such as hyaluronic acid with a
molecular weight greater than 100 kD, are not used in preparing the
liposomes of the present invention, because they were found to
adhere non-covalently to the liposomes.
[0068] In one embodiment, a low molecular weight GAG, such as
sodium hyaluronate is prepared by acid hydrolysis of sodium
hyaluronate as described in Example 9 of WO 2010/132402, which is
incorporated herein by reference in its entirety.
[0069] In one embodiment the molecular weight of hyaluronic acid
and derivatives is determined by size exclusion chromatography and
multi-angle light scattering (SEC-MALS) as described in WO
2010/132402.
[0070] In one embodiment, the polysaccharide is not a
glycosaminoglycan (GAG). In one embodiment, the polysaccharide is
chitosan, alginic acid, hetastarch, dextran, or a combination
thereof.
[0071] In one embodiment, a lipid or phospholipid may be used for
the compositions and methods of the present invention. In one
embodiment, "lipid" refers to any type of lipids including, inter
alia, phospholipids, glycerolipids, sphingolipids, sterol lipids,
prenol lipids, saccharolipids and the like.
[0072] In one embodiment, the polymer-conjugated lipid is a
polymer-conjugated phospholipid. In another embodiment, the
phospholipid is a phosphatidylethanolamine, a phosphatidylserine, a
phosphatidylcholine, a phosphatidylinositol, a phosphatidic acid or
a phosphatidylglycerol. In another embodiment, said phospholipid
comprises the residue of palmitic acid, myristic acid, myristoleic
acid, palmitoleic acid, oleic acid, linoleic acid, linolenic acid,
arachidonic acid, eicosapentaenoic acid, erucic acid or
docosahexaenoic acid.
[0073] In one embodiment, phospholipids for the compositions and
methods of the present invention may have varying chain lengths. In
one embodiment, said phospholipid is a dimyristoyl phospholipid. In
another embodiment, said phospholipid is a dipalmitoyl
phospholipid. In another embodiment, said phospholipid is a
dilauryl-phospholipid. In another embodiment, said phospholipid is
a distearoyl-phospholipid. In another embodiment, said phospholipid
is a dioleoyl-phospholipid.
[0074] In one embodiment, the present invention provides a lipo
some comprising a lipid-polymer conjugate represented by the
structure of the general formula (A):
##STR00001## [0075] wherein [0076] L is a lipid or a phospholipid;
[0077] Z is either nothing, ethanolamine, serine, inositol,
choline, phosphate, or glycerol; [0078] Y is either nothing or a
spacer group ranging in length from 2 to 30 atoms; [0079] X is a
glycosaminoglycan; and [0080] n is a number from 1 to 70; [0081]
wherein any bond between L, Z, Y and X is either an amide or an
esteric bond; [0082] wherein the molecular weight of said
glycosaminoglycan is between 5 kD and 20 kD.
[0083] In one embodiment L is a lipid. In another embodiment L is a
phospholipid. In another embodiment, L is a
phosphatidylethanolamine, a phosphatidylserine, a
phosphatidylcholine, a phosphatidylinositol, a phosphatidic acid or
a phosphatidylglycerol. In another embodiment, L comprises the
residue of palmitic acid, myristic acid, myristoleic acid,
palmitoleic acid, oleic acid, linoleic acid, linolenic acid,
arachidonic acid, eicosapentaenoic acid, erucic acid or
docosahexaenoic acid. In another embodiment, L is dimyristoyl
phosphatidylethanolamine. In another embodiment, said L is
dipalmitoyl phosphatidylethanolamine.
[0084] In another embodiment, X is hyaluronic acid, heparin,
heparan sulfate, chondroitin, chondroitin sulfate, dermatan sulfate
or keratan sulfate. In another embodiment, X is hyaluronic acid. In
another embodiment, X is heparin. In another embodiment, X is
chondroitin. In another embodiment, X is chondroitin sulfate. In
another embodiment, X is dermatan sulfate, in another embodiment, X
is keratan sulfate. In another embodiment, X is Haemaccel,
Alginates, Alginic Acid, Chitosan, or a combination thereof.
[0085] In another embodiment, said chondroitin sulfate is
chondroitin-6-sulfate, chondroitin-4-sulfate or a derivative
thereof. In another embodiment, said dermatan sulfate is
dermatan-6-sulfate, dermatan-4-sulfate or a derivative thereof.
[0086] In one embodiment, X is a polymer that is not a
polysaccharide, which in one embodiment, is Haemaccel. In one
embodiment, X is not PEG.
[0087] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (I):
##STR00002##
wherein [0088] R.sub.1 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0089] R.sub.2 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0090] Y is either nothing or a spacer group ranging in
length from 2 to 30 atoms; and [0091] X is either a physiologically
acceptable monomer, dimer, oligomer or a physiologically acceptable
polymer; and [0092] n is a number from 1 to 1,000; [0093] wherein
if Y is nothing the phosphatidylethanolamine is directly linked to
X via an amide bond and if Y is a spacer, the spacer is directly
linked to X via an amide or an esteric bond and to the
phosphatidylethanolamine via an amide bond.
[0094] In one embodiment, compounds for use in the liposomes of the
invention comprise one of the following as the conjugated moiety X:
acetate, butyrate, glutarate, succinate, dodecanoate,
didodecanoate, maltose, lactobionic acid, dextran, alginate,
aspirin, cholate, cholesterylhemisuccinate,
carboxymethyl-cellulose, heparin, hyaluronic acid, chondroitin
sulfate, polygeline (haemaccel), polyethyleneglycol,
polycarboxylated polyethylene glycol, a glycosaminoglycan, a
polysaccharide, a hetero-polysaccharide, a homo-polysaccharide, or
a polypyranose. The polymers used as starting material to prepare
the PE-conjugates may vary in molecular weight from 1 to 2,000 kDa.
In one embodiment, heparin is ultra low molecular weight heparin,
which in one embodiment, comprises 5-6 disaccharide units.
[0095] Examples of phosphatidylethanolamine (PE) moieties are
analogues of the phospholipid in which the chain length of the two
fatty acid groups attached to the glycerol backbone of the
phospholipid varies from 2-30 carbon atoms length, and in which
these fatty acids chains contain saturated and/or unsaturated
carbon atoms. In lieu of fatty acid chains, alkyl chains attached
directly or via an ether linkage to the glycerol backbone of the
phospholipid are included as analogues of PE. In one embodiment,
the PE moiety is dipalmitoyl-phosphatidyl-ethanolamine. In another
embodiment, the PE moiety is
dimyristoyl-phosphatidyl-ethanolamine.
[0096] Phosphatidyl-ethanolamine and its analogues may be from
various sources, including natural, synthetic, and semisynthetic
derivatives and their isomers.
[0097] Phospholipids which can be employed in lieu of the PE moiety
are N-methyl-PE derivatives and their analogues, linked through the
amino group of the N-methyl-PE by a covalent bond; N,N-dimethyl-PE
derivatives and their analogues linked through the amino group of
the N,N-dimethyl-PE by a covalent bond, phosphatidylserine (PS) and
its analogues, such as palmitoyl-stearoyl-PS, natural PS from
various sources, semisynthetic PSs, synthetic, natural and
artifactual PSs and their isomers. Other phospholipids useful as
conjugated moieties in this invention are phosphatidylcholine (PC),
phosphatidylinositol (PI), phosphatidic acid and
phosphoatidylglycerol (PG), as well as derivatives thereof
comprising either phospholipids, lysophospholipids, phosphatidic
acid, sphingomyelins, lysosphingomyelins, ceramide, and
sphingosine.
[0098] For PE-conjugates and PS-conjugates, the phospholipid is
linked to the conjugated monomer or polymer moiety through the
nitrogen atom of the phospholipid polar head group, either directly
or via a spacer group. For PC, PI, and PG conjugates, the
phospholipid is linked to the conjugated monomer or polymer moiety
through either the nitrogen or one of the oxygen atoms of the polar
head group, either directly or via a spacer group.
[0099] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (II):
##STR00003##
wherein: [0100] R.sub.1 is a linear, saturated, mono-unsaturated,
or poly-unsaturated, alkyl chain ranging in length from 2 to 30
carbon atoms; [0101] R.sub.2 is a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0102] Y is either nothing or a
spacer group ranging in length from 2 to 30 atoms; [0103] X is a
physiologically acceptable monomer, dimer, oligomer or polymer
wherein X is a glycosaminoglycan; and [0104] n is a number from 1
to 1000; [0105] wherein if Y is nothing, the phosphatidylserine is
directly linked to X via an amide bond and if Y is a spacer, the
spacer is directly linked to X via an amide or an esteric bond and
to the phosphatidylserine via an amide bond.
[0106] In one embodiment, the phosphatidylserine may be bonded to
Y, or to X if Y is nothing, via the COO.sup.- moiety of the
phosphatidylserine.
[0107] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (III):
##STR00004##
wherein [0108] R.sub.1 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0109] R.sub.2 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0110] Z is either nothing, inositol, choline, or glycerol;
[0111] Y is either nothing or a spacer group ranging in length from
2 to 30 atoms; [0112] X is a physiologically acceptable monomer,
dimer, oligomer, or polymer wherein X is a glycosaminoglycan; and
[0113] n is a number from 1 to 1000; [0114] wherein any bond
between the phosphatidyl, Z, Y and X is either an amide or an
esteric bond.
[0115] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (IV):
##STR00005##
wherein [0116] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0117] R.sub.2 is a linear,
saturated, mono-unsaturated, or poly-unsaturated, alkyl chain
ranging in length from 2 to 30 carbon atoms; [0118] Z is either
nothing, inositol, choline, or glycerol; [0119] Y is either nothing
or a spacer group ranging in length from 2 to 30 atoms; [0120] X is
a physiologically acceptable monomer, dimer, oligomer, or polymer
wherein X is a glycosaminoglycan; and [0121] n is a number from 1
to 1000; [0122] wherein any bond between the phospholipid, Z, Y and
X is either an amide or an esteric bond.
[0123] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (V):
##STR00006##
wherein [0124] R.sub.1 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0125] R.sub.2 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0126] Z is either nothing,
inositol, choline, or glycerol; [0127] Y is either nothing or a
spacer group ranging in length from 2 to 30 atoms; [0128] X is a
physiologically acceptable monomer, dimer, oligomer, or polymer
wherein X is a glycosaminoglycan; and [0129] n is a number from 1
to 1000; [0130] wherein any bond between the phospholipid, Z, Y and
X is either an amide or an esteric bond.
[0131] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (VI):
##STR00007##
wherein [0132] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0133] R.sub.2 is a linear,
saturated, mono-unsaturated, or poly-unsaturated, alkyl chain
ranging in length from 2 to 30 carbon atoms; [0134] Z is either
nothing, inositol, choline, or glycerol; [0135] Y is either nothing
or a spacer group ranging in length from 2 to 30 atoms; [0136] X is
a physiologically acceptable monomer, dimer, oligomer, or polymer
wherein X is a glycosaminoglycan; and [0137] n is a number from 1
to 1000; [0138] wherein any bond between the phospholipid, Z, Y and
X is either an amide or an esteric bond.
[0139] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (VII):
##STR00008##
wherein [0140] R.sub.1 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0141] R.sub.2 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0142] Z is either nothing,
inositol, choline, or glycerol; [0143] Y is either nothing or a
spacer group ranging in length from 2 to 30 atoms; [0144] X is a
physiologically acceptable monomer, dimer, oligomer, or polymer
wherein X is a glycosaminoglycan; and [0145] n is a number from 1
to 1000; [0146] wherein any bond between the phospholipid, Z, Y and
X is either an amide or an esteric bond.
[0147] In one embodiment of the invention, phosphatidylcholine
(PC), phosphatidylinositol (PI), phosphatidic acid (PA), wherein Z
is nothing, and phosphatidylglycerol (PG) conjugates are herein
defined as compounds of the general formula (III).
[0148] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (VIII):
##STR00009##
wherein [0149] R.sub.1 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0150] R.sub.2 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0151] Z is either nothing,
ethanolamine, serine, inositol, choline, or glycerol; [0152] Y is
either nothing or a spacer group ranging in length from 2 to 30
atoms; [0153] X is a physiologically acceptable monomer, dimer,
oligomer, or polymer wherein X is a glycosaminoglycan; and [0154] n
is a number from 1 to 1000; [0155] wherein any bond between the
phospholipid, Z, Y and X is either an amide or an esteric bond.
[0156] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (IX):
##STR00010##
wherein [0157] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0158] R.sub.2 is either hydrogen
or a linear, saturated, mono-unsaturated, or poly-unsaturated,
alkyl chain ranging in length from 2 to 30 carbon atoms; [0159] Z
is either nothing, ethanolamine, serine, inositol, choline, or
glycerol; [0160] Y is either nothing or a spacer group ranging in
length from 2 to 30 atoms; [0161] X is a physiologically acceptable
monomer, dimer, oligomer, or polymer wherein X is a
glycosaminoglycan; and [0162] n is a number from 1 to 1000; [0163]
wherein any bond between the phospholipid, Z, Y and X is either an
amide or an esteric bond.
[0164] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (IXa):
##STR00011##
wherein [0165] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0166] R.sub.2 is either hydrogen
or a linear, saturated, mono-unsaturated, or poly-unsaturated,
alkyl chain ranging in length from 2 to 30 carbon atoms; [0167] Z
is either nothing, ethanolamine, serine, inositol, choline, or
glycerol; [0168] Y is either nothing or a spacer group ranging in
length from 2 to 30 atoms; [0169] X is a physiologically acceptable
monomer, dimer, oligomer, or polymer wherein X is a
glycosaminoglycan; and [0170] n is a number from 1 to 1000; [0171]
wherein any bond between the phospholipid, Z, Y and X is either an
amide or an esteric bond.
[0172] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (IXb):
##STR00012##
wherein [0173] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0174] R.sub.2 is either hydrogen
or a linear, saturated, mono-unsaturated, or poly-unsaturated,
alkyl chain ranging in length from 2 to 30 carbon atoms; [0175] Z
is either nothing, ethanolamine, serine, inositol, choline, or
glycerol; [0176] Y is either nothing or a spacer group ranging in
length from 2 to 30 atoms; [0177] X is a physiologically acceptable
monomer, dimer, oligomer, or polymer wherein X is a
glycosaminoglycan; and [0178] n is a number from 1 to 1000; [0179]
wherein any bond between the phospholipid, Z, Y and X is either an
amide or an esteric bond.
[0180] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (X):
##STR00013##
wherein [0181] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0182] R.sub.2 is a linear,
saturated, mono-unsaturated, or poly-unsaturated, alkyl chain
ranging in length from 2 to 30 carbon atoms; [0183] Z is either
nothing, ethanolamine, serine, inositol, choline, or glycerol;
[0184] Y is either nothing or a spacer group ranging in length from
2 to 30 atoms; [0185] X is a physiologically acceptable monomer,
dimer, oligomer, or polymer wherein X is a glycosaminoglycan; and
[0186] n is a number from 1 to 1000; [0187] wherein any bond
between the ceramide phosphoryl, Z, Y and X is either an amide or
an esteric bond.
[0188] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XI):
##STR00014##
wherein [0189] R.sub.1 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0190] Y is either nothing or a spacer group ranging in
length from 2 to 30 atoms; [0191] X is a physiologically acceptable
monomer, dimer, oligomer or polymer wherein X is a
glycosaminoglycan; and [0192] n is a number from 1 to 1000; [0193]
wherein if Y is nothing the sphingosyl is directly linked to X via
an amide bond and if Y is a spacer, the spacer is directly linked
to X and to the sphingosyl via an amide bond and to X via an amide
or an esteric bond.
[0194] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XII):
##STR00015##
wherein [0195] R.sub.1 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0196] R.sub.2 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0197] Z is either nothing, ethanolamine, serine, inositol,
choline, or glycerol; [0198] Y is either nothing or a spacer group
ranging in length from 2 to 30 atoms; [0199] X is a physiologically
acceptable monomer, dimer, oligomer or polymer wherein X is a
glycosaminoglycan; and [0200] n is a number from 1 to 1000; [0201]
wherein any bond between the ceramide, Z, Y and X is either an
amide or an esteric bond.
[0202] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XIII):
##STR00016##
wherein [0203] R.sub.1 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0204] R.sub.2 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0205] Z is either nothing, choline, phosphate, inositol, or
glycerol; [0206] Y is either nothing or a spacer group ranging in
length from 2 to 30 atoms; [0207] X is a physiologically acceptable
monomer, dimer, oligomer or polymer wherein X is a
glycosaminoglycan; and [0208] n is a number from 1 to 1000; [0209]
wherein any bond between the diglyceryl, Z, Y and X is either an
amide or an esteric bond.
[0210] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XIV):
##STR00017##
wherein [0211] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0212] R.sub.2 is a linear,
saturated, mono-unsaturated, or poly-unsaturated, alkyl chain
ranging in length from 2 to 30 carbon atoms; [0213] Z is either
nothing, choline, phosphate, inositol, or glycerol; [0214] Y is
either nothing or a spacer group ranging in length from 2 to 30
atoms; [0215] X is a physiologically acceptable monomer, dimer,
oligomer or polymer wherein X is a glycosaminoglycan; and [0216] n
is a number from 1 to 1000; [0217] wherein any bond between the
glycerolipid, Z, Y and X is either an amide or an esteric bond.
[0218] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XV):
##STR00018##
wherein [0219] R.sub.1 is a linear, saturated, mono-unsaturated, or
poly-unsaturated, alkyl chain ranging in length from 2 to 30 carbon
atoms; [0220] R.sub.2 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0221] Z is either nothing,
choline, phosphate, inositol, or glycerol; [0222] Y is either
nothing or a spacer group ranging in length from 2 to 30 atoms;
[0223] X is a physiologically acceptable monomer, dimer, oligomer
or polymer wherein X is a glycosaminoglycan; and [0224] n is a
number from 1 to 1000; [0225] wherein any bond between the
glycerolipid, Z, Y and X is either an amide or an esteric bond.
[0226] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XVI):
##STR00019##
wherein [0227] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0228] R.sub.2 is a linear,
saturated, mono-unsaturated, or poly-unsaturated, alkyl chain
ranging in length from 2 to 30 carbon atoms; [0229] Z is either
nothing, choline, phosphate, inositol, or glycerol; [0230] Y is
either nothing or a spacer group ranging in length from 2 to 30
atoms; [0231] X is a physiologically acceptable monomer, dimer,
oligomer or polymer wherein X is a glycosaminoglycan; and [0232] n
is a number from 1 to 1000; [0233] wherein any bond between the
lipid, Z, Y and X is either an amide or an esteric bond.
[0234] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XVII):
##STR00020##
wherein [0235] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0236] R.sub.2 is a linear,
saturated, mono-unsaturated, or poly-unsaturated, alkyl chain
ranging in length from 2 to 30 carbon atoms; [0237] Z is either
nothing, choline, phosphate, inositol, or glycerol; [0238] Y is
either nothing or a spacer group ranging in length from 2 to 30
atoms; [0239] X is a physiologically acceptable monomer, dimer,
oligomer or polymer wherein X is a glycosaminoglycan; and [0240] n
is a number from 1 to 1000; [0241] wherein any bond between the
lipid, Z, Y and X is either an amide or an esteric bond.
[0242] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XVIII):
##STR00021##
wherein [0243] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0244] R.sub.2 is either hydrogen
or a linear, saturated, mono-unsaturated, or poly-unsaturated,
alkyl chain ranging in length from 2 to 30 carbon atoms; [0245] Z
is either nothing, choline, phosphate, inositol, or glycerol;
[0246] Y is either nothing or a spacer group ranging in length from
2 to 30 atoms; [0247] X is a physiologically acceptable monomer,
dimer, oligomer or polymer wherein X is a glycosaminoglycan; and
[0248] n is a number from 1 to 1000; [0249] wherein any bond
between the lipid, Z, Y and X is either an amide or an esteric
bond.
[0250] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XIX):
##STR00022##
wherein [0251] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0252] R.sub.2 is either hydrogen
or a linear, saturated, mono-unsaturated, or poly-unsaturated,
alkyl chain ranging in length from 2 to 30 carbon atoms; [0253] Z
is either nothing, choline, phosphate, inositol, or glycerol;
[0254] Y is either nothing or a spacer group ranging in length from
2 to 30 atoms; [0255] X is a physiologically acceptable monomer,
dimer, oligomer or polymer wherein X is a glycosaminoglycan; and
[0256] n is a number from 1 to 1000; [0257] wherein any bond
between the lipid, Z, Y and X is either an amide or an esteric
bond.
[0258] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XX):
##STR00023##
wherein [0259] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0260] R.sub.2 is either hydrogen
or a linear, saturated, mono-unsaturated, or poly-unsaturated,
alkyl chain ranging in length from 2 to 30 carbon atoms; [0261] Z
is either nothing, choline, phosphate, inositol, or glycerol;
[0262] Y is either nothing or a spacer group ranging in length from
2 to 30 atoms; [0263] X is a physiologically acceptable monomer,
dimer, oligomer or polymer wherein X is a glycosaminoglycan; and
[0264] n is a number from 1 to 1000; [0265] wherein any bond
between the lipid, Z, Y and X is either an amide or an esteric
bond.
[0266] In another embodiment, the present invention provides a
liposome comprising a lipid-polymer conjugate represented by the
structure of the general formula (XXI):
##STR00024##
wherein [0267] R.sub.1 is either hydrogen or a linear, saturated,
mono-unsaturated, or poly-unsaturated, alkyl chain ranging in
length from 2 to 30 carbon atoms; [0268] R.sub.2 is either hydrogen
or a linear, saturated, mono-unsaturated, or poly-unsaturated,
alkyl chain ranging in length from 2 to 30 carbon atoms; [0269] Z
is either nothing, choline, phosphate, inositol, or glycerol;
[0270] Y is either nothing or a spacer group ranging in length from
2 to 30 atoms; [0271] X is a physiologically acceptable monomer,
dimer, oligomer or polymer wherein X is a glycosaminoglycan; and
[0272] n is a number from 1 to 1000; [0273] wherein any bond
between the lipid, Z, Y and X is either an amide or an esteric
bond.
[0274] For any or all of the compounds represented by the
structures of the general formulae (A), (I), (II), (III), (IV),
(V), (VI), (VII), (VIII), (IX), (IXa), (IXb), (X), (XI), (XII),
(XIII), (XIV), (XV), (XVI), (XVII), (XVIII), (XIX), (XX), (XXI),
and (XXII) hereinabove: In one embodiment, X is a
glycosaminoglycan. According to this aspect and in one embodiment,
the glycosaminoglycan may be, inter alia, hyaluronic acid, heparin,
heparan sulfate, chondroitin sulfate, keratin, keratan sulfate,
dermatan sulfate or a derivative thereof. In another embodiment, X
is not a glycosaminoglycan. hi another embodiment, X is a
polysaccharide, which in one embodiment is a hetero-polysaccharide,
and in another embodiment, is a homo-polysaccharide. In another
embodiment, X is a polypyranose.
[0275] In another embodiment, the glycosaminoglycan is a polymer of
disaccharide units. In another embodiment, the number of the
disaccharide units in the polymer is m. In another embodiment, m is
a number from 2-10,000. In another embodiment, m is a number from
2-500. In another embodiment, m is a number from 2-1000. In another
embodiment, m is a number from 50-500. In another embodiment, m is
a number from 2-2000. In another embodiment, m is a number from
500-2000. In another embodiment, m is a number from 1000-2000. In
another embodiment, m is a number from 2000-5000. In another
embodiment, m is a number from 3000-7000. In another embodiment, m
is a number from 5000-10,000. In another embodiment, a disaccharide
unit of a glycosaminoglycan may be bound to one lipid or
phospholipid moiety. In another embodiment, each disaccharide unit
of the glycosaminoglycan may be bound to zero or one lipid or
phospholipid moieties. In another embodiment, the lipid or
phospholipid moieties are bound to the --COOH group of the
disaccharide unit. In another embodiment, the bond between the
lipid or phospholipid moiety and the disaccharide unit is an amide
bond.
[0276] In another embodiment, the glycosaminoglycan comprises di-
or trisaccharide unit monomers of glycosaminoglycans.
[0277] In another embodiment, the chondroitin sulfate may be, inter
alia, chondroitin-6-sulfate, chondroitin-4-sulfate or a derivative
thereof.
[0278] In one embodiment of the invention, Y is nothing.
Non-limiting examples of suitable divalent groups forming the
optional bridging group (which in one embodiment, is referred to as
a spacer) Y, according to embodiments of the invention, are
straight or branched chain alkylene, e.g., of 2 or more, preferably
4 to 30 carbon atoms, --CO-alkylene-CO, --NH-alkylene-NH--,
--CO-alkylene-NH--, --NH-alkylene-NH, CO-alkylene-NH--, an amino
acid, cycloalkylene, wherein alkylene in each instance, is straight
or branched chain and contains 2 or more, preferably 2 to 30 atoms
in the chain, --(--O--CH(CH.sub.3)CH.sub.2--).sub.x-- wherein x is
an integer of 1 or more.
[0279] According to embodiments of the invention, in addition to
the traditional phospholipid structure, related derivatives for use
in this invention are phospholipids modified at the C1 or C2
position to contain an amine, ether or alkyl bond instead of an
ester bond. In one embodiment of the invention, the alkyl
phospholipid derivatives and ether phospholipid derivatives are
exemplified herein.
[0280] In one embodiment of the invention, the sugar rings of the
phospholipid-bound glycosaminoglycan are intact. In another
embodiment, intact refers to closed. In another embodiment, intact
refers to natural. In another embodiment, intact refers to
unbroken.
[0281] In one embodiment of the invention, the structure of the
lipid or phospholipid in any compound according to the invention is
intact. In another embodiment, the natural structure of the lipid
or phospholipids in any compound according to the invention is
maintained.
[0282] In one embodiment, the compounds for use in the present
invention are biodegradable.
[0283] In some embodiments, the compounds for use are as listed in
Table 1 below.
TABLE-US-00001 TABLE 1 Sample Polymer-conjugated Lipids.
Phospholipid Spacer Polymer (m.w.) Compound PE None Hyaluronic acid
(2-2000 kDa) XXII Dimyristoyl-PE None Hyaluronic acid XXIII PE None
Heparin (0.7-110 kDa) XXIV PE None Chondroitin sulfate A XXV PE
None Carboxymethylcellulose (20-500 XXVI kDa) PE Dicarboxylic acid
+ Polygeline (haemaccel) (4-100 XXVII Diamine kDa) PE None
Hydroxyethylstarch XXVIII PE Dicarboxylic acid + Dextran (1-2,000
kDa) XXIX Diamine PE None Aspirin XXX PE Carboxyl amino Hyaluronic
acid (2-2000 kDa) XXXI group PE Dicarboxyl group Hyaluronic acid
(2-2000 kDa) XXXII PE Dipalmitoic acid Hyaluronic acid (2-2000 kDa)
XXXIII PE Carboxyl amino Heparin (0.5-110 kDa) XXXIV group PE
Dicarboxyl group Heparin (0.5-110 kDa) XXXV PE Carboxyl amino
Chondroitin sulfate A XXXVI group PE Dicarboxyl group Chondroitin
sulfate A XXXVII PE Carboxyl amino Carboxymethylcellulose (20-500
XXXVIII group kDa) PE Dicarboxyl group Carboxymethylcellulose
(20-500 XXXIX kDa) PE None Polygeline (haemaccel) (4-100 XL kDa) PE
Carboxyl amino Polygeline (haemaccel) (4-40 XLI group kDa) PE
Dicarboxyl group Polygeline (haemaccel) (4-40 XLII kDa) PE Carboxyl
amino Hydroxyethylstarch XLIII group PE Dicarboxyl group
Hydroxyethylstarch XLIV PE None Dextran (1-2,000 kDa) XLV PE
Carboxyl amino Dextran (1-2,000 kDa) XLVI group PE Dicarboxyl group
Dextran (1-2,000 kDa) XLVII PE Carboxyl amino Aspirin XLVIII group
PE Dicarboxyl group Aspirin XLIX PE None Albumin L PE None Alginate
(2-2000 kDa) LI PE None Polyaminoacid LII PE None Polyethylene
glycol LIII PE None Lactobionic acid LIV PE None Acetylsalicylate
LV PE None Cholesteryl-hemmisuccinate LVI PE None Maltose LVII PE
None Cholic acid LVIII PE None Chondroitin sulfates LIX PE None
Polycarboxylated polyethylene LX glycol Dipalmitoyl-PE None
Hyaluronic acid LXI Dipalmitoyl-PE None Heparin LXII Dipalmitoyl-PE
None Chondroitin sulfate A LXIII Dipalmitoyl-PE None
Carboxymethylcellulose LXIV Dipalmitoyl-PE None Polygeline
(haemaccel) LXV Dipalmitoyl-PE None Hydroxyethylstarch LXVI
Dipalmitoyl-PE None Dextran LXVII Dipalmitoyl-PE None Aspirin
LXVIII Dimyristoyl-PE None Heparin LXVIX Dimyristoyl-PE None
Chondroitin sulfate A LXX Dimyristoyl-PE None
Carboxymethylcellulose LXXI Dimyristoyl-PE None Polygeline
(haemaccel) LXXII Dimyristoyl-PE None Hydroxyethylstarch LXXIII
Dimyristoyl-PE None Dextran LXXIV Dimyristoyl-PE None Aspirin LXXV
PS None Hyaluronic acid LXXVI PS None Heparin LXXVII PS None
Polygeline (haemaccel) LXXVIII PC None Hyaluronic acid LXXIX PC
None Heparin LXXX PC None Polygeline (haemaccel) LXXXI PI None
Hyaluronic acid LXXXII PI None Heparin LXXXIII PI None Polygeline
(haemaccel) LXXXIV PG None Hyaluronic acid LXXXV PG None Heparin
LXXXVI PG None Polygeline (haemaccel) LXXXVII PE None Glutaryl
LXXXVIII PE Amino Acid Hyaluronic Acid LXXXVIX PE Amino Acid
Chondroitin Sulfate XC PE Amino Acid Dermatan Sulfate XCI PE Amino
Acid Heparin XCII PS Amino Acid Hyaluronic Acid XCIII PS Amino Acid
Chondroitin Sulfate XCIV PS Amino Acid Dermatan Sulfate XCV PS
Amino Acid Heparin XCVI PC Amino Acid Hyaluronic Acid XCVII PC
Amino Acid Chondroitin Sulfate XCVIII PC Amino Acid Dermatan
Sulfate XCIX PC Amino Acid Heparin C PE Amino Acid Alginate (2-2000
kDa) CI PE None Dermatan Sulfate CII PS None Dermatan Sulfate CIII
PC None Dermatan Sulfate CIV PI None Dermatan Sulfate CV PG None
Dermatan Sulfate CVI PE None Chitosan CVII PS None Chitosan CVIII
PC None Chitosan CIX PI None Chitosan CX PG None Chitosan CXI PE
Dicarboxylic Acid Chitosan CXII PS Dicarboxylic Acid Chitosan CXIII
PC Dicarboxylic Acid Chitosan CXIV PI Dicarboxylic Acid Chitosan
CXV PG Dicarboxylic Acid Chitosan CXVI
[0284] In one embodiment, a GAG and a PL for use in the
compositions and methods of the present invention comprise a
spacer, which in one embodiment, is an amino acid, wherein the
amino group of the amino acid binds to a carboxy group of the GAG
and the carboxy group of the amino acid binds to an amino group of
the phospholipids.
[0285] In one embodiment of the invention, the compounds for use in
the present invention are any one or more of Compounds I-LXXXVIII.
In another embodiment, the compounds for use in the present
invention are Compound XXII, Compound XXIII, Compound XXIV,
Compound XXV, Compound XXVI, Compound XXVII, Compound XXVIII,
Compound XXIX, Compound XXX, or pharmaceutically acceptable salts
thereof, in combination with a physiologically acceptable carrier
or solvent. According to embodiments of the invention, these
polymers, when chosen as the conjugated moiety, may vary in
molecular weights from 200 to 2,000,000 Daltons. In one embodiment
of the invention, the molecular weight of the polymer as referred
to herein is from 200 to 1000 Daltons. In another embodiment, the
molecular weight of the polymer as referred to herein is from 200
to 1000 Daltons. In another embodiment, the molecular weight of the
polymer as referred to herein is from 1000 to 5000 Daltons. In
another embodiment, the molecular weight of the polymer as referred
to herein is from 5000 to 10,000 Daltons. In another embodiment,
the molecular weight of the polymer as referred to herein is from
10,000 to 20,000 Daltons. In another embodiment, the molecular
weight of the polymer as referred to herein is from 10,000 to
50,000 Daltons. In another embodiment, the molecular weight of the
polymer as referred to herein is from 20,000 to 70,000 Daltons. In
another embodiment, the molecular weight of the polymer as referred
to herein is from 50,000 to 100,000 Daltons. In another embodiment,
the molecular weight of the polymer as referred to herein is from
100,000 to 200,000 Daltons. In another embodiment, the molecular
weight of the polymer as referred to herein is from 200,000 to
500,000 Daltons. In another embodiment, the molecular weight of the
polymer as referred to herein is from 200,000 to 1,000,000 Daltons.
In another embodiment, the molecular weight of the polymer as
referred to herein is from 500,000 to 1,000,000 Daltons. In another
embodiment, the molecular weight of the polymer as referred to
herein is from 1,000,000 to 2,000,000 Daltons. Various molecular
weight species have been shown to have the desired biological
efficacy.
[0286] In one embodiment of this invention, low molecular weight
Lipid-conjugates are defined hereinabove as the compounds of
formula (I)-(XXI) wherein X is a mono- or disaccharide,
carboxylated disaccharide, mono- or dicarboxylic acids, a
salicylate, salicylic acid, aspirin, lactobionic acid, maltose, an
amino acid, glycine, acetic acid, butyric acid, dicarboxylic acid,
glutaric acid, succinic acid, fatty acid, dodecanoic acid,
didodecanoic acid, bile acid, cholic acid,
cholesterylhemmisuccinate, a di- or tripeptide, an oligopeptide, a
trisacharide, or a di- or trisaccharide monomer unit of heparin,
heparan sulfate, keratin, keratan sulfate, chondroitin,
chondroitin-6-sulfate, chondroitin-4-sulfate, dermatin, dermatan
sulfate, dextran, hyaluronic acid, glycosaminoglycan, or
polypyranose.
[0287] Examples of suitable divalent groups forming the optional
bridging group Y are straight- or branched-chain alkylene, e.g., of
2 or more, preferably 4 to 18 carbon atoms, CO alkylene-CO,
--NH-alkylene-NH--, --CO-alkylene-NH--, cycloalkylene, wherein
alkylene in each instance, is straight or branched chain and
contains 2 or more, preferably 2 to 18 carbon atoms in the chain,
--(O--CH(CH.sub.3)CH.sub.2--).sub.x-- wherein x is an integer of 1
or more.
[0288] In another embodiment, in addition to the traditional
phospholipid structure, related derivatives for use in this
invention are phospholipids modified at the C1 or C2 position to
contain an ether or alkyl bond instead of an ester bond. These
derivatives arc exemplified hereinabove by the general formulae
(VIII) and (IX).
[0289] In one embodiment of the invention, X is covalently
conjugated to a lipid. In another embodiment, X is covalently
conjugated to a lipid via an amide bond. In another embodiment, X
is covalently conjugated to a lipid via an esteric bond. In another
embodiment, the lipid is phosphatidylethanolamine.
[0290] In one embodiment, the present invention provides a liposome
comprising a polymer-conjugated lipid, which in one embodiment, is
a polysaccharide-conjugated phospholipid (PoS-PL). In one
embodiment, said PoS-PL is hyaluronic
acid-phosphatidyl-ethanolamine (HyPE; Compound A), which in one
embodiment, comprises alternating N-acetyl-D-glucosamine and
D-glucuronic acid residues joined by alternating
beta-1,3-glucuronidic and beta-1,4-glucosaminidic bonds.
##STR00025##
[0291] In one embodiment derivatives of hyaluronic acid such as
those obtained from chemical modification by salification, partial
and/or total esterification, inner esterification, deacetylation,
O-sulphatation, percarboxylation and amidation may be used in the
compositions and methods of the present invention. In one
embodiment, "n" describes the number of PEs present in the whole
HyPE-conjugated PE molecule, while "m" describes the number of
disaccharides present in the molecule, wherein some of the
disaccharide units comprise a conjugated HyPE, and other
disaccharide units do not comprise a conjugated HyPE.
[0292] In another embodiment, said PoS-PL is Chondroitin
Sulfate-phosphatidyl-ethanolamine (CSAPE; Compound B).
##STR00026##
[0293] In another embodiment, said PoS-PL is Dermatan
Sulfate-phosphatidyl-ethanolamine (DerPE; Compound C).
##STR00027##
[0294] In another embodiment, said PoS-PL is
Heparin-phosphatidyl-ethanolamine (HepPE; Compound D).
##STR00028##
[0295] In another embodiment, said PoS-PL is a
non-glycosaminoglycan-conjugated phospholipid.
[0296] In another embodiment, said PoS-PL is
Chitosan-Glutaryl-phosphatidyl-ethanolamine (ChiPF; Compound
E).
##STR00029##
[0297] In another embodiment, said PoS-PL is Alginic
acid-phosphatidyl-ethanolamine (AlgPE; Compound F).
##STR00030##
[0298] In another embodiment, said PoS-PL is
Hetastarch-Glutaryl-phosphatidyl-ethanolamine (HetPE; Compound
G).
##STR00031##
[0299] In another embodiment, said PoS-PL is
Dextran-Glutaryl-phosphatidyl-ethanolamine (DexPE; Compound H).
##STR00032##
[0300] In another embodiment, said Po-L is
Haemaccel-Glutaryl-phosphatidyl-ethanolamine (HemPE or polygeline;
Compound I).
##STR00033##
[0301] In one embodiment, said PoS-PL is keratan
sulfate-phosphatidyl-ethanolamine (KSPE; Compound J).
##STR00034##
[0302] In another embodiment, said PoS-PL is a lipid or
phospholipid conjugate as described in US Publication No.
US2010/0022473, which is incorporated herein by reference.
[0303] In one embodiment, a polysaccharide is linked to a
phospholipid through an amine residue of the phospholipid. In one
embodiment, a polysaccharide is linked to a phospholipid through a
carboxylic acid residue of the polysaccharide. In another
embodiment, a polysaccharide is linked to a phospholipid via a
hydroxyl units (e.g., --CH.sub.2--OH), which may be oxidized to an
aldehyde in the absence of a crosslinking reagent.
[0304] In one embodiment, liposomes are hollow microspheres of
varying size, ranging between 50 rim and 1000 nm, formed by one or
more double lipid layers that enclose a hydrophilic core. This
structure can be achieved thanks to the special nature of
phospholipids that have a hydrophobic tail and hydrophilic head; in
an aqueous medium the hydrophobic tails attract one another while
the hydrophilic heads tend to face water. The result is double
lipid layers that close to form small vesicles inside which there
is a variously hydrophilic environment. Liposomes were first
described in 1965 (Standish M M et al., J Mol Biol, 1965,
13:238-252) and have been researched as carriers for drugs and/or
active ingredients (e.g., Liposomes as drug carriers, Gregoriadis
G. editor, New York: John Wiley & Sons, 1985: 3-18; Banerjee
R., J Biomater Appl, 2001, 16:3-21). They are normally classified
on the basis of their size and the number of double lipid layers.
Generally speaking, as described, for example, by Callow R A et al.
(Cryobiology, 1985:251-267, incorporated herein by reference),
reference is made to a) multilamellar vesicles: they have an
onion-like structure wherein a number of double lipid layers are
interspersed with hydrophilic layers; b) unilamellar vesicles,
large (diameter of over 1 .mu.m) and small (diameter of less than 1
.mu.m): they are formed by one single double lipid layer and
enclose a strongly hydrophilic nucleus; c) oligolamellar vesicles,
constituted by several double lipid layers that enclose a markedly
hydrophobic environment.
[0305] In one embodiment, liposomes, which in one embodiment are,
multilamellar vesicles (MLV), microemulsified liposomes (MEL) or
large unilamellar vesicles (LUVET), are prepared using methods
known in the art. In one embodiment, said liposomes do not comprise
phosphatidylethanolamine (PE). In another embodiment, said
liposomes comprise phosphatidylethanolamine.
[0306] In one embodiment, the classic lipid film technique for the
production of unilamellar liposomes was used to prepare liposomes:
the lipids selected that will constitute the double layer are mixed
with an organic solvent and then exposed to set environmental
conditions (for example, set parameters of pressure and
temperature) so as to allow the solvent to evaporate and the dry
lipid film to form. The lipid film is then hydrated with an aqueous
medium and/or with the solution containing the polymer to be
associated with the liposomes. One part of the mixture is frozen,
freeze-dried and then reconstituted to its initial volume by adding
a suitable medium. The step of freezing, freeze-drying and
reconstituting was devised on the basis of experimental findings
(Peer at al., Biochim Biophys Acta, 2003, 1612:76-82, incorporated
herein by reference) demonstrating that hyaluronic acid and/or the
derivatives thereof can act as cryoprotectors for the unilamellar
liposome microstructures. Generally, when simple,
structured-phospholipid suspensions are freeze-dried and then
reconstituted, the liposomes lose their original characteristics,
and become organized in far larger multilamellar vesicles, that are
unsuitable for the purposes of the present invention because their
structure and the controlled release of the material they are
carrying are ineffective. The presence in the mixture to be
freeze-dried of significant quantities of polysaccharides conserves
the original structural properties of the liposomes by the
formation of stabilizing hydrogen bonds and maintains their
efficacy as controlled release systems following their
reconstitution.
[0307] In another embodiment, liposomes of the present invention
may be obtained by any method known to the skilled artisan. In one
embodiment, liposomes of appropriate size are prepared using
sonication/ultrasound, extrusion, or a combination thereof.
[0308] In another embodiment, the lipo some preparation can be
produced by reverse phase evaporation (REV) method (see U.S. Pat.
No. 4,235,871, incorporated herein by reference), infusion
procedures, or detergent dilution. A review of these and other
methods for producing liposomes may be found in the text Liposomes,
Marc Ostro, ed., Marcel Dekker, Inc., New York, 1983, Chapter 1,
incorporated herein by reference. See also Szoka Jr. et al., (1980,
Ann. Rev. Biophys. Bioeng., 9:467), incorporated herein by
reference. A method for forming ULVs is described in Cullis et al.,
PCT Publication No. 87/00238, Jan. 16, 1986, entitled "Extrusion
Technique for Producing Unilamellar Vesicles", incorporated herein
by reference. Multilamellar liposomes (MLV) may be prepared by the
lipid-film method, wherein the lipids are dissolved in a
chloroform-methanol solution (3:1, vol/vol), evaporated to dryness
under reduced pressure and hydrated by a swelling solution. Then,
the solution is subjected to extensive agitation and incubation,
e.g., 2 hour, e.g., at 37.degree. C. After incubation, unilamellar
liposomes (ULV) are obtained by extrusion. The extrusion step
modifies liposomes by reducing the size of the liposomes to a
preferred average diameter. Alternatively, liposomes of the desired
size may be selected using techniques such as filtration or other
size selection techniques.
[0309] While the size-selected liposomes of the invention should
have an average diameter of less than about 300 nm, it is preferred
that they are selected to have an average diameter of less than
about 200 nm with an average diameter of less than about 100 nm
being particularly preferred. When the liposome of the present
invention is a unilamellar liposome, it preferably is selected to
have an average diameter of less than about 200 nm. The most
preferred unilamellar liposomes of the invention have an average
diameter of less than about 100 nm. It is understood, however, that
multivesicular liposomes of the invention derived from smaller
unilamellar liposomes will generally be larger and may have an
average diameter of about less than 1000 nm. Preferred
multivesicular liposomes of the invention have an average diameter
of less than about 800 nm, and less than about 500 nm while most
preferred multivesicular liposomes of the invention have an average
diameter of less than about 300 nm.
[0310] In one embodiment, the liposomes are formed by a lipid
constituted by a hydrophilic part and a lipophilic part that may
have a single or multiple, saturated or unsaturated, linear or
branched chain, of natural or synthetic origin. Other elements may
be added, such as cholesterol, which stabilize the liposomes in the
biological fluids, or any other element known to the expert in the
field to have the desired effect.
[0311] In one embodiment, a liposome of the present invention
comprises two or more lateral lipophilic chains. In one embodiment,
a liposome of the present invention comprises the lipophilic
cationic chains that contain two saturated and/or unsaturated fatty
acids with, for example, between 10 and 30 carbon atoms, the salts
of fatty acids with quaternary amines, quaternary
dimethyldiacylamines where the acyl groups contain between 8 and 30
carbon atoms. Further examples are amply described in the
literature (including Fasbender et al., Am J Physiol, 1995,
269:L45-L51; Solodin et al, Biochemistry, 1995, 34:13537-13544;
Feigner et al., J Biol Chem, 1994, 269:2550-2561; Stamatatos et
al., Biochemistry, 1988, 27:3917-3925, incorporated herein by
reference in their entirety).
[0312] In one embodiment, a liposome of the present invention
comprises non-ionic chains, which in one embodiment are glyceric
diesters with, for example, between 10 and 30 carbon atoms, and in
another embodiment, are alkoxylated amines. In one embodiment,
examples of anionic lateral chains including phosphatidic acids and
negatively charged phospholipids such as
dipalmitoylphosphatidylglycerol. In one embodiment, examples of
substances with a single, non-ionic chain are monoglyceric esters
with between 10 and 30 carbon atoms in the chain, such as glyceryl
caprate, caprylate, hydroxystearate, lysostearate, lanolate,
laurate, linolate, etc.
[0313] In another embodiment, liposomes are constituted by
polyoxyethylene derivatives to which lipophilic chains are bound by
ether and/or ester bonds. For illustrative purposes we can mention
cetyl and stearic ethers, and all those with between 3 and 10
oxyethylene units, and the derivatives thereof.
[0314] The substances with a single anionic chain include, but are
not limited to, fatty acids such as oleic acid and negatively
charged phospholipids with a single chain such as
phosphatidylserine and phosphatidylglycerol.
[0315] In one embodiment, the liposome may be constituted by
phospholipids of either natural or synthetic origin. Natural
phospholipids include egg phosphatidylcholine, as such or
hydrogenated, and phospholipids from soya or other vegetal
sources.
[0316] Liposomes according to the invention may be produced from
combinations of lipid materials well known and routinely utilized
in the art to produce liposomes. Lipids may include relatively
rigid varieties, such as sphingomyelin, or fluid types, such as
phospholipids having unsaturated acyl chains. "Phospholipid" refers
to any one phospholipid or combination of phospholipids capable of
forming liposomes. Phosphatidylcholines (PC), including those
obtained from egg, soy beans or other plant sources or those that
are partially or wholly synthetic, or of variable lipid chain
length and unsaturation are suitable for use in the present
invention. Synthetic, semisynthetic and natural product
phosphatidylcholines including, but not limited to,
distearoylphosphatidylcholine (DSPC), hydrogenated soy
phosphatidylcholine (HSPC), soy phosphatidylcholine (soy PC), egg
phosphatidylcholine (egg PC), hydrogenated egg phosphatidylcholine
(HEPC), dipalmitoylphosphatidylcholine (DPPC),
dimyristoylphosphatidylcholine (DMPC)
dimiristoylglycerophosphocholine (DMPC),
dilauroylglycerophosphocholine (DLPC),
palmitoyloleoylglycerophospho-choline (POPC),
phosphatidylethanolamine, dipalmitoylphosphatidylglycerol (DPPG),
dipalmitoylphosphatidic acid (DPPA), and phosphatidylserine are
suitable phosphatidylcholines for use in this invention. All of
these phospholipids are commercially available. Further,
phosphatidylglycerols (PG) and phosphatic acid (PA) are also
suitable phospholipids for use in the present invention and
include, but are not limited to, dimyristoylphosphatidylglycerol
(DMPG), dilaurylphosphatidylglycerol (DLPG),
dipalmitoylphosphatidylglycerol (DPPG),
distearoylphosphatidylglycerol (DSPG) dimyristoylphosphatidic acid
(DMPA), distearoylphosphatidic acid (DSPA), dilaurylphosphatidic
acid (DLPA), and dipalmitoylphosphatidic acid (DPPA). In another
embodiment, liposomes are composed of
di-oleoyl-phosphatidyl-choline (DOPC), PC labeled with C.sub.6-NBD
(a fluorescent fatty acid) at carbon 2, or a combination thereof.
In another embodiment, liposomes are composed of dimyristoyl
phosphatidyl-choline (DMPC). Other suitable phospholipids include
phosphatidylethanolamines, phosphatidylinositols, sphingomyelins,
and phosphatidic acids containing lauric, myristic, stearoyl, and
palmitic acid chains. For the purpose of stabilizing the lipid
membrane, it is preferred to add an additional lipid component,
such as cholesterol. In one embodiment, lipids for producing
liposomes according to the invention include
phosphatidylethanolamine (PE) and phosphatidylcholine (PC) in
further combination with cholesterol (CH). According to one
embodiment of the invention, a combination of lipids and
cholesterol for producing the liposomes of the invention comprise a
PE:PC:Chol molar ratio of 3:1:1.
[0317] In one embodiment, in order to prevent the uptake of the
liposomes into the cellular endothelial systems and enhance the
uptake of the liposomes into the tissue of interest, the outer
surface of the liposomes may be modified with a long-circulating
agent. The modification of the liposomes with a hydrophilic polymer
as the long-circulating agent is known to enable to prolong the
half-life of the liposomes in the blood. Examples of the
hydrophilic polymer include polyethylene glycol, polymethylethylene
glycol, polyhydroxypropylene glycol, polypropylene glycol,
polymethylpropylene glycol and polyhydroxypropylene oxide. Thus, in
one embodiment, incorporation of polyethylene glycol (PEG)
containing phospholipids is also contemplated by the present
invention.
[0318] Clearly, there are a multitude of possible combinations that
can be made to obtain liposomes that are suitable for the purpose
and, since they have already been amply reported in the literature,
a technical expert in the field will be able to choose the most
suitable.
[0319] In one embodiment, the compounds according to the invention
are biodegradable.
Methods of Producing Polymer-Conjugated Lipid Liposomes
[0320] In another embodiment, the present invention provides a
method of producing a mixed liposome comprising the step of
conjugating a lipid with a polymer to form a polymer-conjugated
lipid and contacting said polymer-conjugated lipid with a liposome
to produce a mixed liposome.
[0321] In another embodiment, the present invention provides a
method of producing a modified liposome comprising the step of
conjugating a lipid with a polymer to form a polymer-conjugated
lipid and contacting said polymer-conjugated lipid with a liposome
to produce a modified liposome. In one embodiment, the method
further comprises the step of isolating said polymer-conjugated
lipid prior to the step of contacting the PoS-PL with the liposome.
In one embodiment, the liposome comprises two or more
polymer-conjugated lipids.
[0322] In another embodiment, the present invention provides a
mixed liposome produced by the method comprising the step of
conjugating a lipid with a polymer to form a polymer-conjugated
lipid and contacting said polymer-conjugated lipid with a liposome
to produce a mixed liposome.
Methods of Producing Liposomes
[0323] In one embodiment, liposomes are prepared by providing
phospholipids in an aqueous environment and allowing said
phospholipids to form liposomes. In one embodiment, energy is
supplied to speed the generation of liposomes. Thus, in one
embodiment, sonication, extrusion, and Mozafari methods may be
employed to produce liposomes. In one embodiment, liposomes may be
made using Phospholipon 90H, Phospholipon 100H,
dipalmitoylphosphatidylcholine (DPPC), stearylamine (SA), dicetyl
phosphate (DCP), cholesterol, or a combination thereof.
Methods of Producing Nanoliposomes
[0324] In on embodiment, in order to separate the liposomes, the
particles are fractionated by successive centrifugations, each run
at 4.degree. C., for 40 minutes at the g force of
1.3.times.10.sup.5, as follows: The pellet after 3 runs is the
microparticle-enriched fraction, the supernatant of the
microparticle enriched fraction subjected to 3 additional runs is
the nanoparticle-enriched fraction.
[0325] In one embodiment, the liposomes may be lyophilized.
Methods of Producing a Polymer-Conjugated Lipid
[0326] In one embodiment, a crosslinking reagent is used to link a
polymer to a lipid. In one embodiment, the crosslinking reagents
comprise glutaraldehyde (GAD), a water soluble carbodiimide, which
in one embodiment is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
(EDC), genipin, transglutaminase, formaldehyde or a combination
thereof.
[0327] In one embodiment, a polymer is conjugated to a lipid
directly or via a linker. In one embodiment, the linker is a
glutaryl linker, which in one embodiment, is represented by the
following formula: --OC(CH.sub.2).sub.3CO--. In another embodiment,
--CO-alkylene-CO, --NH-alkylene-NH--, --CO-alkylene-NH--,
--NH-alkylene-NHCO-alkylene-NH--, an amino acid, cycloallcylene,
wherein alkylene in each instance, is straight or branched chain
and comprises 2 or more, preferably 2 to 30 atoms in the chain,
--(--O--CH(CH.sub.3)CH.sub.2--).sub.x--, wherein x is an integer of
1 or more.
[0328] In one embodiment, the linkage between the polymer, in one
embodiment, a polysaccharide, and the lipid, in one embodiment a
phospholipids, is an amide linkage. In another embodiment, the
linkage between the polysaccharide and the phospholipid is an ester
linkage.
[0329] In one embodiment, polymer-conjugated lipids are combined
with liposomes in solution, wherein the lipid component of the
polymer-conjugated lipids integrates into the lipid bilayer of the
liposomes. In one embodiment, the polymers anchored to the surface
of the liposome via the covalently bound lipids radiate from the
liposome surface (i.e., perpendicular to the liposome surface) like
a mushroom (FIG. 1a). In one embodiment, the mushroom structure
results from a comparatively low Po-L/liposome ratio, wherein the
Po-Ls are less densely packed. In one embodiment, the polymers
anchored to the surface of the liposome via the covalently bound
lipids radiate from the liposome surface (i.e., perpendicular to
the liposome surface) like a brush (FIG. 1b). In one embodiment,
the brush structure results from a comparatively high Po-L/liposome
ratio, wherein the Po-Ls are crowded together. In one embodiment,
the Po-L/liposome ratio is adjusted so that there is an
intermediate structure, a mushroom-brush structure, which in one
embodiment, provides a protection of approximately 3-10 nm. In one
embodiment, the lipid-conjugated polymers form a protective layer
of approximately 3-10 nm (FIGS. 1a-1b), which, in one embodiment,
protects the liposome from degrading enzymes or other
injurious/lytic agents, such as phospholipase A2 (PLA2), as was
demonstrated herein (FIG. 4). In another embodiment, the
lipid-conjugated polymers form a layer greater than 1 nm on the
liposome. In another embodiment, the lipid-conjugated polymers form
a layer of approximately 3.5 nm. In another embodiment, the
lipid-conjugated polymers form a layer of approximately 4.5 nm. In
another embodiment, the lipid-conjugated polymers form a layer of
approximately 3.5-4.5 nm. In another embodiment, the
lipid-conjugated polymers form a layer of approximately 3-5 nm. In
another embodiment, the lipid-conjugated polymers form a layer of
approximately 2-7 nm. Lipid-conjugated polymers are known in the
art to act as PLA2 inhibitors, and the data presented herein
demonstrates that lipid-conjugated polymers can also protect
liposomes from degradation.
[0330] This is in contrast to large polysaccharides, such as
native, non-truncated hyaluronic acid, which coat the outer surface
of a liposome, forming a layer of approximately 1 nm (FIG. 1c),
which is not sufficient to protect liposomes from many enzymes. In
addition, it is known in the art that liposomes formed from mixing
polymers with lipids even in the presence of cross-linking agents
may result in an adhesion of polymers to the surface of said
liposomes rather than the integration of polymer-liposome
conjugates into the liposome.
Uses of Polymer-Conjugated Lipid Liposomes
[0331] In one embodiment, the present invention provides a drug
delivery system comprising a liposome comprising a
polymer-conjugated lipid.
[0332] In another embodiment, the present invention provides a drug
delivery system comprising a liposome comprising a lipid bilayer
and a polymer-conjugated lipid, wherein said polymer-conjugated
lipid is incorporated into said lipid bilayer.
[0333] In another embodiment, the present invention provides a drug
delivery system comprising a liposome comprising two or more
polymer-conjugated lipids, wherein said polymer-conjugated lipid
comprises two or more lipids conjugated to a single polymer.
[0334] In another embodiment, the present invention provides a drug
delivery system comprising a liposome comprising two or more low
molecular weight glycosaminoglycan (GAG)-conjugated lipids, wherein
said low molecular weight GAG-conjugated lipid comprises two or
more lipids conjugated to a single GAG.
[0335] In another embodiment, the present invention provides a drug
delivery system comprising a liposome comprising a
polymer-conjugated lipid, wherein said polymer is not a
glycosaminoglycan.
[0336] In one embodiment, the polymer-conjugated lipid increases
the stability of the liposome, which in one embodiment, comprises a
bioactive drug. In another embodiment, the polymer-conjugated lipid
decreases degradation of the liposome. In another embodiment, the
polymer-conjugated lipid increases the half-life of the liposome.
In another embodiment, the liposome targets the bioactive
polymer-conjugated lipid to inflamed tissue, thereby increasing the
effectiveness of the polymer-conjugated lipid. In one embodiment,
the liposome comprising the bioactive polymer-conjugated lipid
further comprises an additional bioactive drug. In one embodiment,
the liposome targets inflamed tissue due to its size, which allows
it to enter inflamed but is not able to enter non-inflamed
tissue.
[0337] In one embodiment, any of the liposomes of and for use in
the methods of this invention comprises one or more
polymer-conjugated lipids of the present invention. Thus, in one
embodiment, a liposome of the present invention comprises HyPE and
KSPE. In another embodiment, a liposome of the present invention
comprises CSAPE and PEG-PE. In another embodiment, a liposome of
the present invention comprises HyPE and PEG-PE. It is to be
understood that a liposome of the present invention may comprise
two, three, four, or more different polymer-conjugated lipids of
the present invention integrated into a lipid bilayer of said
liposome.
[0338] In one embodiment, the liposomes of the present invention
comprise a hydrophobic agent in the lipid layer.
[0339] In another embodiment, the liposomes of the present
invention comprise a hydrophilic agent encapsulated within the
liposome.
[0340] In one embodiment, the agent is a nucleic acid, such as
plasmid DNA, short interfering RNA (siRNA), short-hairpin RNA,
small temporal RNA (stRNA), microRNA (miRNA), RNA mimetics, or
heterochromatic siRNA condensed with a cationic peptide, such as a
protamine sulfate and polylysine or a cationic polymer, such as
polyethyleneimine (PEI), polyamine spermidine, and spermine.
[0341] In one embodiment, compositions of the present invention may
be used as microscopic drug delivery systems (MDDS). In another
embodiment, compositions of the present invention provide sustained
or controlled release of therapeutic or diagnostic drugs. In
another embodiment, compositions of the present invention reduce
drug degradation or inactivation. In another embodiment,
compositions of the present invention improve drug efficacy and
allow reduction in the frequency of dosing of a drug. In another
embodiment, compositions of the present invention reduce toxicity
and undesirable side effects of a drug. In another embodiment,
compositions of the present invention encapsulate drugs for
subsequent delivery for use in therapy and diagnosis. In another
embodiment, compositions of the present invention improve the
efficiency and decrease the side effects of drugs, vaccines,
cosmetics, slimming agents or nutraceuticals. In another
embodiment, compositions of the present invention are able to
incorporate and protect various types of bioactives as well as
deliver them to the target site inside the human or animal
body.
[0342] In one embodiment, small molecules, such as antibiotics and
chemotherapeutic drugs, and large molecules, such as proteins, can
be encapsulated in the modified liposomes described herein. In
another embodiment, the modified liposomes can be used to
encapsulate DNA, and the larger the modified liposomes may even
encapsulate whole cells and cell lines. Thus, the modified
liposomes can also be used as a scaffold for tissue
engineering.
[0343] In another embodiment of the present invention, other
molecules may be attached first to the polysaccharide, which is
then reacted with lipids. These particles have the other molecules
appearing on the outside of the particles. These other molecules
may be, for example, antibodies, folate, porphyrins, or lectins,
and may be used for targeting. In another embodiment, a targeting
agent may be attached to the polysaccharide, which in one
embodiment is a specific monoclonal antibody, scFv, Fab fragment,
receptor ligand, or combination thereof.
[0344] In one embodiment, a polysaccharide of the present invention
may be conjugated with antibodies against MUC1, MUC2, or MUC3 for
targeting to tumors of breast, lung, and prostate cancers.
Alternately, a polysaccharide of the present invention may be
conjugated with antibodies against ganglio side GM3 for targeting
to melanoma.
[0345] In one embodiment, the present invention provides a method
for encapsulating one or more agents in a liposome. The method
comprises the steps of: (1) providing a lyophilized liposome having
lipids conjugated with a polymer, wherein the polymer is covalently
linked to the lipid (2) providing a hydrophilic agent in aqueous
solution; and (3) rehydrating the lyophilized liposome with the
aqueous solution comprising the hydrophilic agent. In one
embodiment, the polymer-conjugated lipid may further comprise a
targeting moiety covalently linked to the polymer-conjugated
lipid.
[0346] The present invention also provides kits for making
liposomes comprising polymer-conjugated lipids and as well as kits
for drug and/or agent encapsulation comprising a liposome and a
polymer-conjugated lipid.
[0347] In another embodiment, the present invention provides a
method for treating a subject suffering from a pathological
condition, comprising administering to said subject a bioactive
agent encapsulated in a liposome comprising a polymer-conjugated
lipid.
[0348] In another embodiment, the present invention provides a
method for treating, inhibiting, or suppressing a pathological
condition in a subject, comprising administering to said subject a
bioactive agent encapsulated in a liposome comprising a
polymer-conjugated lipid.
[0349] In another embodiment, the present invention provides a
method for treating, inhibiting, or suppressing a pathological
condition in a subject, comprising administering to said subject a
liposome comprising a lipid bilayer and a polymer-conjugated lipid,
wherein said polymer-conjugated lipid is incorporated into said
lipid bilayer. In one embodiment, the liposome comprises an agent
that is effective in treating, inhibiting, or suppressing said
pathological condition.
[0350] In another embodiment, the present invention provides a
method for treating, inhibiting, or suppressing a pathological
condition in a subject, comprising administering to said subject a
bioactive agent encapsulated in a liposome comprising two or more
polymer-conjugated lipids, wherein said polymer-conjugated lipid
comprises two or more lipids conjugated to a single polymer.
[0351] In another embodiment, the present invention provides a
method for treating, inhibiting, or suppressing a pathological
condition in a subject, comprising administering to said subject a
bioactive agent encapsulated in a liposome comprising two or more
low molecular weight glycosaminoglycan (GAG)-conjugated lipids,
wherein said low molecular weight GAG-conjugated lipid comprises
two or more lipids conjugated to a single GAG.
[0352] In another embodiment, the present invention provides a
method for treating, inhibiting, or suppressing a pathological
condition in a subject, comprising administering to said subject a
bioactive agent encapsulated in a liposome comprising a
polymer-conjugated lipid, wherein said polymer is not a
glycosaminoglycan.
[0353] In one embodiment, the therapeutic or prophylactic effect of
the liposome is due to the natural targeting of nanoliposomes to
inflamed tissue. According to this aspect and in one embodiment, a
nanoliposome targets the polymer-conjugated lipid to inflamed
tissue where the polymer-conjugated lipid exerts an
anti-inflammatory effect, thereby initiating a therapeutic or
prophylactic effect in the subject. In another embodiment, the
liposome comprises a bioactive agent, and the improved effect of
the compositions and methods of the present invention is due to the
protection from degradation endowed by the polymer-conjugated lipid
on the liposome, thereby increasing the half-life of the liposome
in a subject, thereby enhancing its effect on said subject. In
another embodiment, the improved effect of the compositions and
methods of the present invention is due to the slower release of
the bioactive agent from the liposome due to the presence of
polymer-conjugated lipids integrated into a lipid bilayer of the
liposome.
[0354] In one embodiment, the pathological condition is sepsis.
[0355] In another embodiment, the pathological condition is an
intestinal disease, which in one embodiment, is Crohn's Disease,
ulcerative colitis, immuno-inflammatory intestinal injury,
drug-induced enteropathy, ischemia-induced intestinal injury,
inflammatory bowel disease, or a combination thereof.
[0356] In another embodiment, the pathological condition is a
disease or disorder of the central nervous system or the peripheral
nervous system associated with an inflammatory response, which in
one embodiment, is multiple sclerosis, Amyotrophic Lateral
Sclerosis (ALS), meningitis, demyelinating diseases of the central
and peripheral nervous system, or any combination thereof, wherein
said demyelinating diseases of the central and peripheral nervous
system comprise multiple sclerosis, idiopathic demyelinating
polyneuropathy or Guillain-Barre syndrome, Alzheimer's disease,
pain, Huntington's disease (HD), myasthenia gravis (MG),
HIV-associated dementia, fronto-temporal dementia (FTD), stroke,
traumatic brain injury, age-related retinal degeneration,
encephalomyelitis, chronic inflammatory demyelinating
polyneuropathy, cerebral ischemia-induced injury, or a combination
thereof.
[0357] In another embodiment, the pathological condition is an
obstructive respiratory disease, which in one embodiment, is
asthma, chronic obstructive pulmonary disease, or a combination
thereof.
[0358] In another embodiment, the pathological condition is a
dermatological condition, which in one embodiment, is psoriasis,
seboreic dermatitis, contact dermatitis, atopic dermatitis, or a
combination thereof.
[0359] In another embodiment, the pathological condition is an
infection. In one embodiment, the infection is viral. In one
embodiment, the viral infection is an influenza infection, an HIV
infection, or a poxvirus infection. In another embodiment, the
infection is bacterial. In one embodiment, the bacterial infection
is a Chlamydia infection.
[0360] In another embodiment, the pathological condition is a
neoplasia. In another embodiment, the pathological condition is
sarcoma, an adenocarcinoma, colon carcinoma, melanoma, breast
carcinoma, leukemia, lymphoma, gastric carcinoma, glioblastoma,
astrocytoma, bladder carcinoma, pleural mesothelioma, oat cell
carcinoma, bronchogenic carcinoma, or a combination thereof.
[0361] In another embodiment, the present invention provides a
method for treating, inhibiting or suppressing a disease, condition
or disorder in a subject, comprising administering to said subject
a bioactive agent encapsulated in a liposome of the present
invention. In one embodiment, the condition is conjunctivitis,
which in one embodiment, is viral and in another embodiment, is
bacterial. In another embodiment, the conjunctivitis is due to an
allergen or to an irritant.
[0362] In another embodiment, the pathological condition is cystic
fibrosis.
[0363] In one embodiment, the pathological condition is cancer and
said bioactive agent is an anticancer drug. In one embodiment, the
cancer is a metastatic cancer. In another embodiment, the
pathological condition is an infection, which in one embodiment, is
a bacterial infection, a fungal infection, a viral infection, or a
parasitic infection. In one embodiment, the bioactive agent is an
antibacterial drug, an antifungal drug, an antiviral drug or an
antiparasitic drug. In another embodiment, the pathological
condition is a prion infection.
[0364] In one embodiment, the drug is administered orally,
intravenously, intranasally, intraocularly, intramuscularly, or
subcutaneously or topically.
[0365] In one embodiment, "treating" refers to either therapeutic
treatment or prophylactic or preventative measures, wherein the
object is to prevent or lessen the targeted pathologic condition or
disorder as described hereinabove. Thus, in one embodiment,
treating may include directly affecting or curing, suppressing,
inhibiting, preventing, reducing the severity of, delaying the
onset of, reducing symptoms associated with the disease, disorder
or condition, or a combination thereof. Thus, in one embodiment,
"treating" refers inter alia to delaying progression, expediting
remission, inducing remission, augmenting remission, speeding
recovery, increasing efficacy of or decreasing resistance to
alternative therapeutics, or a combination thereof. In one
embodiment, "preventing" refers, inter alia, to delaying the onset
of symptoms, preventing relapse to a disease, decreasing the number
or frequency of relapse episodes, increasing latency between
symptomatic episodes, or a combination thereof. In one embodiment,
"suppressing" or "inhibiting", refers inter alia to reducing the
severity of symptoms, reducing the severity of an acute episode,
reducing the number of symptoms, reducing the incidence of
disease-related symptoms, reducing the latency of symptoms,
ameliorating symptoms, reducing secondary symptoms, reducing
secondary infections, prolonging patient survival, or a combination
thereof.
[0366] In one embodiment, symptoms are primary, while in another
embodiment, symptoms are secondary. In one embodiment, "primary"
refers to a symptom that is a direct result of the subject viral
infection, while in one embodiment, "secondary" refers to a symptom
that is derived from or consequent to a primary cause. In one
embodiment, the compositions and methods for use in the present
invention treat primary or secondary symptoms or secondary
complications related the pathological condition.
[0367] In some embodiments, any of the liposomes of and for use in
the methods of this invention will comprise one or more
polymer-conjugated lipids of the present invention, in any form or
embodiment as described herein. In some embodiments, any of the
liposomes of this invention will consist of one or more
polymer-conjugated lipids of the present invention, in any form or
embodiment as described herein. In some embodiments, the liposomes
of this invention will consist essentially of one or more
polymer-conjugated lipids of the present invention, in any form or
embodiment as described herein.
[0368] In some embodiments, the term "comprise" refers to the
inclusion of a polymer-conjugated lipid, such as HyPE, as well as
inclusion of other lipids or lipid conjugates that may be known in
the art. In some embodiments, the term "consisting essentially of"
refers to a liposome, whose only variation from a standard liposome
is the indicated inclusion of a polymer-conjugated lipid, however,
other lipids or lipid conjugates may be included that are not
involved directly in the improved drug release profile of the
liposome. In some embodiments, the term "consisting" refers to a
liposome, which contains only a particular a polymer-conjugated
lipid, or alternatively, only the recited polymer-conjugated lipids
integrated into the liposome.
[0369] In one embodiment, the term "targeting agent" or "targeting
moiety" refers to an agent that homes in on or preferentially
associates or binds to a particular tissue, cell type, receptor,
infecting agent or other area of interest. Examples of a targeting
agent include, but are not limited to, an oligonucleotide, an
antigen, an antibody or functional fragment thereof, a ligand, a
receptor, one member of a specific binding pair, a polyamide
including a peptide having affinity for a biological receptor, an
oligosaccharide, a polysaccharide, a steroid or steroid derivative,
a hormone, e.g., estradiol or histamine, a hormone-mimic, e.g.,
morphine, or other compound having binding specificity for a
target. In the methods of the present invention, the targeting
agent promotes transport or preferential localization of the lipid
particle of the present invention to the target of interest.
[0370] As used herein, an "antibody" or "functional fragment" of an
antibody encompasses polyclonal and monoclonal antibody
preparations, as well as preparations including hybrid or chimeric
antibodies, such as humanized antibodies, altered antibodies,
F(ab').sub.2 fragments, F(ab) fragments, Fv fragments, single
domain antibodies, dimeric and trimeric antibody fragment
constructs, minibodies, and functional fragments thereof which
exhibit immunological binding properties of the parent antibody
molecule and/or which bind a cell surface antigen.
[0371] The targeting agent can be any ligand the receptor for which
is differentially expressed on the target cell. Non-limiting
examples include transferrin, folate, other vitamins, EGF, insulin,
Heregulin, RGD peptides or other polypeptides reactive to integrin
receptors, antibodies or their fragments. Sugar molecules or
glycoproteins, lipid molecules or lipoproteins may be targeting
agents.
[0372] In one embodiment, antibodies against cell surface markers
that are specifically expressed in disease states can be used as
targeting agent. Examples of antigens that specifically appear in
tumors cells include ganglioside GM3 on melanoma, MUC1, MUC2, and
MUC3 on the surface of breast cancer, lung cancer and prostate
cancer, and Lewis X on the surface of gastro-intestinal digestive
cancer. In one embodiment the antibody is a functional fragment
containing the antigen binding region of the antibody. A preferred
antibody fragment is a single chain Fv fragment of an antibody. The
antibody or antibody fragment is one which will bind to a receptor
on the surface of the target cell, and preferably to a receptor
that is differentially expressed on the target cell. In one
embodiment, multiple types of targeting agents may be covalently
attached to the lipid particle.
[0373] In another embodiment, the present invention provides a
method for performing diagnostic imaging in a subject, comprising
the step of administering a diagnostic agent encapsulated in a
liposome comprising a polymer-conjugated lipid.
[0374] In another embodiment, the present invention provides a
method for performing diagnostic imaging in a subject, comprising
the step of administering a diagnostic agent encapsulated in a
liposome comprising a lipid bilayer and a polymer-conjugated lipid,
wherein said polymer-conjugated lipid is incorporated into said
lipid bilayer to said subject and imaging said patient.
[0375] In another embodiment, the present invention provides a
method for performing diagnostic imaging in a subject, comprising
the step of administering a diagnostic agent encapsulated in a
liposome comprising two or more polymer-conjugated lipids, wherein
said polymer-conjugated lipid comprises two or more lipids
conjugated to a single polymer.
[0376] In another embodiment, the present invention provides a
method for performing diagnostic imaging in a subject, comprising
the step of administering a diagnostic agent encapsulated in a
liposome comprising two or more low molecular weight
glycosaminoglycan (GAG)-conjugated lipids, wherein said low
molecular weight GAG-conjugated lipid comprises two or more lipids
conjugated to a single GAG.
[0377] In another embodiment, the present invention provides a
method for performing diagnostic imaging in a subject, comprising
the step of administering a diagnostic agent encapsulated in a
liposome comprising a polymer-conjugated lipid, wherein said
polymer is not a glycosaminoglycan.
[0378] In another embodiment, the present invention provides a
method for inhibiting PLA2 in a subject comprising the step of
administering to said subject a liposome comprising a
polymer-conjugated lipid.
[0379] In another embodiment, the present invention provides a
method for inhibiting PLA2 in a subject comprising the step of
administering to said subject a liposome comprising two or more
polymer-conjugated lipids, wherein said polymer-conjugated lipid
comprises two or more lipids conjugated to a single polymer.
[0380] In another embodiment, the present invention provides a
method for inhibiting PLA2 in a subject comprising the step of
administering to said subject a liposome comprising two or more low
molecular weight glycosaminoglycan (GAG)-conjugated lipids, wherein
said low molecular weight GAG-conjugated lipid comprises two or
more lipids conjugated to a single GAG.
[0381] In another embodiment, the present invention provides a
method for inhibiting PLA2 in a subject comprising the step of
administering to said subject a liposome comprising a
polymer-conjugated lipid, wherein said polymer is not a
glycosaminoglycan.
[0382] In one embodiment, the terms "encapsulation" and
"entrapped," as used herein, refer to the incorporation of an agent
in a lipid particle. The agent is present in the aqueous interior
of the lipid particle. In one embodiment, a portion of the
encapsulated agent takes the form of a precipitated salt in the
interior of the liposome. The agent may also self precipitate in
the interior of the liposome.
[0383] In one embodiment, "agent" means any agent or compound that
can affect the body therapeutically, or which can be used in vivo
for diagnosis. Examples of therapeutic agents include
chemotherapeutics for cancer treatment, antibiotics for treating
infections, antifungals for treating fungal infections, therapeutic
nucleic acids including nucleic acid analogs, e.g., siRNA. In one
embodiment, the agent of interest is a gene, polynucleotide, such
as plasmid DNA, DNA fragment, oligonucleotide,
oligodeoxynucleotide, antisense oligonucleotide, chimeric RNA/DNA
oligonucleotide, RNA, siRNA, ribozyme, or viral particle. In one
embodiment, the agent is a growth factor, cytokine,
immunomodulating agent, or other protein, including proteins which
when expressed present an antigen which stimulates or suppresses
the immune system. In one embodiment, the agent is a diagnostic
agent capable of detection in vivo following administration.
Exemplary diagnostic agents include electron dense material,
magnetic resonance imaging agents, radiopharmaceuticals and
fluorescent molecules. Radionucleotides useful for imaging include
radioisotopes of copper, gallium, indium, rhenium, and technetium,
including isotopes .sup.64Cu, .sup.67Cu, .sup.111In, .sup.99mTc,
.sup.67Ga or .sup.68Ga. Imaging agents disclosed by Low et al. in
U.S. Pat. No. 5,688,488, incorporated herein by reference, are
useful in the liposomal complexes described herein.
[0384] In one embodiment, the agent of interest is a nucleic acid,
e.g., DNA, RNA, siRNA, plasmid DNA, short-hairpin RNA, small
temporal RNA (stRNA), microRNA (miRNA), RNA mimetics, or
heterochromatic siRNA. The nucleic acid agent of interest has a
charged backbone that prevents efficient encapsulation in the lipid
particle. Accordingly, the nucleic acid agent of interest may be
condensed with a cationic polymer, e.g., PEI, polyamine spermidine,
and spermine, or cationic peptide, e.g., protamine and polylysine,
prior to encapsulation in the lipid particle. In one embodiment,
the agent is not condensed with a cationic polymer.
[0385] In one embodiment, the agent of interest is encapsulated in
the lipid particle in the following manner. The lipid particle,
including a cryoprotectant and a targeting agent is provided
lyophilized. The agent of interest is in an aqueous solution. The
agent of interest in aqueous solution is utilized to rehydrate the
lyophilized lipid particle. Thus, the agent of interest is
encapsulated in the rehydrated lipid particle.
[0386] In one embodiment, two agents of interest may be delivered
by the lipid particle. One agent is hydrophobic and the other is
hydrophilic. The hydrophobic agent may be added to the lipid
particle during formation of the lipid particle. The hydrophobic
agent associates with the lipid portion of the lipid particle. The
hydrophilic agent is added in the aqueous solution rehydrating the
lyophilized lipid particle.
[0387] Any suitable lipid:pharmaceutical agent ratio that is
efficacious is contemplated by this invention. In one embodiment,
lipid:pharmaceutical agent molar ratios include about 2:1 to about
30:1, about 5:1 to about 100:1, about 10:1 to about 40:1, about
15:1 to about 25:1.
[0388] In one embodiment, the loading efficiency of pharmaceutical
agent is a percent encapsulated pharmaceutical agent of about 50%,
about 60%, about 70% or greater. In one embodiment, the loading
efficiency for a hydrophilic agent is a range from 50-100%. The
preferred loading efficiency of pharmaceutical agent associated
with the lipid portion of the lipid particle, e.g., a
pharmaceutical agent poorly soluble in aqueous solution, is a
percent loaded pharmaceutical agent of about 50%, about 60%, about
70%, about 80%, about 90%, about 100%. In one embodiment, the
loading efficiency for a hydrophobic agent in the lipid layer is a
range from 80-100%.
[0389] In one aspect of the method, the liposome product is
detectably labeled with a label selected from the group including a
radioactive label, a fluorescent label, a non-fluorescent label, a
dye, or a compound which enhances magnetic resonance imaging (MRI).
In one embodiment, the liposome product is detected by acoustic
reflectivity. The label may be attached to the exterior of the
liposome or may be encapsulated in the interior of the
liposome.
[0390] In another embodiment, the present invention provides a
method of delivering a nucleic acid to a subject comprising the
step of administering said nucleic acid encapsulated in a liposome
comprising a lipid bilayer and a polymer-conjugated lipid, wherein
said polymer-conjugated lipid is incorporated into said lipid
bilayer to said subject.
[0391] In another embodiment, the present invention provides a
method of delivering a nucleic acid to a subject comprising the
step of administering said nucleic acid encapsulated in a modified
liposome comprising a lipid bilayer, wherein said liposome
comprises two or more polysaccharide-conjugated phospholipids
(PoS-PLs) incorporated into said lipid bilayer to said subject.
[0392] It is still another object of the present invention to
provide gene delivery using lipid particles as the gene delivery
materials. For example, the mutant Raf gene can be targeted and
delivered to tumor cells for anti-angiogenic purposes; the gene for
the highly ctoxic cytokine TNF-alpha may be delivered to cancers to
promote cell death; genes for the cytokines IL-12 and IFN-.gamma.
can be delivered to the lungs for allergy-induced
hyperesponsiveness (AHR); and the cDNA for the glail cell ine
derived neurogrowth factor (GDNF) may be targeted to the dopamine
cells at the substantia nigra in Parkinson's disease patients.
[0393] In one embodiment, liposomes of the present invention are
used to deliver anti-cancer agents. In one embodiment, liposomes
comprising HYPE and containing a mitotic inhibitor such as
Paclitaxel is encompassed in the compositions and related methods
of the present invention. In one embodiment, numerous human tumor
types, including ovarian cancer, breast cancer, non-small cell lung
cancer, colorectal cancer, head and neck cancers, and other
malignancies, have a significant expression of the CD44 family of
cell-surface proteoglycans. For example, the CD44 proteoglycan
family is expressed in as many as about 90% of fresh samples from
primary human ovarian tumors or peritoneal implants. Additionally,
studies with squamous cell carcinomas of the head and neck have
shown up to 75% to have expression of CD44. Typically, epithelial
cancer stem cells also express CD44.
[0394] The CD44 proteoglycan family includes a parental form and 10
or more isoforms that are major receptors for hyaluronic acid.
Hyaluronic acid serves a variety of functions within the
extracellular matrix, including direct receptor-mediated effects on
cell behavior. These effects occur via intracellular signaling
pathways in which hyaluronic acid binds to, and is internalized by,
CD44 cell surface receptors.
[0395] As used herein, the term "anti-cancer agent" refers to a
compound capable of negatively affecting cancer in a subject, for
example, by killing one or more cancer cells, inducing apoptosis in
one or more cancer cells, reducing the growth rate of one or more
cancer cells, reducing the incidence or number of metastases,
reducing a tumor's size, inhibiting a tumor's growth, reducing the
blood supply to a tumor or one or more cancer cells, promoting an
immune response against one or more cancer cells or a tumor,
preventing or inhibiting the progression of a cancer, or increasing
the lifespan of a subject with a cancer.
[0396] In some embodiments, anti-cancer agents suitable for use in
the modified liposomes of the present disclosure comprise a taxane.
In general, taxanes typically are diterpenes with antineoplastic
properties, such as the inhibition of microtubule function.
Examples of suitable taxanes include, but are not limited to,
paclitaxel, docetaxel, and derivatives thereof. In one embodiment,
a suitable anti-cancer agent may be present as an active ester,
such as a N-hydroxysuccinimide ester ("NHS ester"). For example, in
one embodiment, a suitable anti-cancer agent may be
paclitaxel-N-hydroxysuccinimide ester, also referred to as
"paclitaxel-NHS ester" or "Taxol-NHS ester." In another embodiment,
the anti-cancer agent to be delivered using the liposomes of the
present invention is Doxorubicin, Topotecan, or a combination
thereof.
[0397] Other anti-cancer agents may also be suitable for use in the
disclosed modified liposomes. Anti-cancer agents include, for
example, chemotherapy agents (chemotherapy), radiotherapy agents
(radiotherapy), immune therapy agents (immunotherapy), genetic
therapy agents (gene therapy), hormonal therapy, other biological
agents (biotherapy) and/or alternative therapies. A non-exhaustive
list of anti-cancer agents which may be suitable for use as an
anti-cancer agent in the modified liposomes disclosed herein may be
found in U.S. Pat. No. 7,344,829, column 12, line 43 through column
13, line 4, incorporated herein by reference.
[0398] In one embodiment, the present invention provides a
composition comprising a liposome of the present invention.
[0399] The phrase "therapeutically effective" is intended to
qualify the amount of active ingredients used in the treatment of a
disease or disorder. This amount will achieve the goal of reducing
or eliminating the said disease or disorder.
[0400] The pharmaceutical composition of the present invention can
be used to treat an indication, i.e., a pathological condition, in
a subject in need thereof. The term "subject" as used herein is
taken to include humans and other mammals such as cattle, sheep,
pigs, goats, dogs, cats, rats, mice, etc., as well as animals
including amphibians, birds, reptiles and fish.
[0401] The pharmaceutical composition according to the present
invention is preferably administered orally but may also be
administered by another suitable route, including parenteral, e.g.,
subcutaneous, intravenous, topical, intramuscular, intraperitoneal,
transdermal, rectal, vaginal, intranasal or intraocular.
Alternatively or concomitantly, administration may be by the oral
route. Oral routes of administration are understood to include
buccal and sublingual routes of administration.
[0402] Parenteral administration can be by bolus injection or by
gradual perfusion over time. Parenteral administration is generally
characterized by injection, most typically subcutaneous,
intramuscular or intravenous.
[0403] Topical formulations composed of the active ingredient of
the pharmaceutical composition of the present invention,
penetration enhancers, and other biologically active drugs or
medicaments may be applied in many ways. A liquid formation can be
applied dropwise, from a suitable delivery device, to the
appropriate area of skin or diseased skin or mucous membranes and
rubbed in by hand or simply allowed to air dry. A suitable gelling
agent can be added to the liquid formulation and the preparation
can be applied to the appropriate area and rubbed in. For
administration to wounds or burns, the active ingredient may be
incorporated into dosage forms such as oils, emulsions, and the
like. Such preparations may be applied directly to the affected
area in the form of lotions, creams, pastes, ointments, and the
like.
[0404] Alternatively, the topical liquid formulation can be placed
into a spray device and be delivered as a spray. This type of drug
delivery device is particularly well suited for application to
large areas of skin affected by dermal pathologies, to highly
sensitive skin or to the nasal or oral cavities. Optionally, the
pharmaceutical composition may be administered in the form of an
ointment or transdermal patch.
[0405] The pharmaceutical composition of the present invention may
also be administered by other routes which optimize uptake by the
mucosa, e.g., vaginal (especially in the case of treating vaginal
pathologies), rectal and intranasal routes of administration.
Furthermore, the pharmaceutical composition may be adapted for
delivery through mucosal tissue or epithelia. If administered
intranasally, the pharmaceutical composition will typically be
administered in an aerosol form, or in the form of drops. This may
be especially useful for treating lung pathologies.
[0406] Suitable formulations can be found in A. Gennaro (2000)
"Remington: The Science and Practice of Pharmacy", 20th edition,
Lippincott, Williams, & Wilkins; Pharmaceutical Dosage Forms
and Drug Delivery Systems (1999) H. C. Ansel et al., eds 7.sup.th
ed., Lippincott, Williams, & Wilkins; and Handbook of
Pharmaceutical Excipients (2000) A. H. Kibbe et al., eds.,3rd ed.
Amer. Pharmaceutical Assoc. each of which is incorporated herein by
reference.
[0407] Depending on the intended mode of administration, the
composition used may be in the form of solid, semi-solid or liquid
dosage forms, such as for example, tablets, suppositories, pills,
capsules, powders, liquids, suspensions, or the like, preferably in
unit dosage forms suitable for single administration of precise
dosages. The pharmaceutical composition of the present invention
and a pharmaceutically acceptable diluent, carrier, excipient,
adjuvant, or auxiliary agent. It is preferred that the
pharmaceutically acceptable carrier be one which is chemically
inert to the active therapeutic protein and which has no
detrimental side effects or toxicity under the conditions of use.
The choice of carrier is determined partly by the particular active
ingredient, as well as by the particular method used to administer
the composition. Accordingly, there are a wide variety of suitable
formulations of the pharmaceutical compositions of the present
invention.
[0408] Suitable excipients are, in particular, fillers such as
saccharides (e.g., lactose or sucrose, mannitol, sorbitol, etc.)
cellulose preparations and/or calcium phosphates (e.g., tricalcium
phosphate, calcium hydrogen phosphate, etc.) as well as binders
such as starch paste using, for example, maize starch, wheat
starch, rice starch, potato starch, gelatin, tragacanth,
methylcellulose, hydroxypropylmethylcellulose, sodium
carboxymethylcellulose, and/or polyvinyl pyrrolidine.
[0409] Injectable formulations for parenteral administration can be
prepared as liquid suspensions, solid forms suitable for solution
or suspension in liquid prior to injection, or as emulsions.
Suitable excipients are, for example, water, saline, dextrose,
glycerol, ethanol or the like. In addition, if desired, the
pharmaceutical composition to be administered may also contain
minor amounts of non-toxic auxiliary agents such as wetting or
emulsifying agents, pH buffering agents and the like, such as for
example, sodium acetate, sorbitan monolaurate, triethanolamine
oleate, etc.
[0410] Aqueous injection suspensions may also contain substances
that increase the viscosity of the suspension, including, for
example, sodium carboxymethylcellulose, sorbitol, and/or dextran.
Optionally, the suspension may also contain stabilizers.
[0411] The parenteral formulations can be present in unit dose or
multiple dose sealed containers, such as ampules and vials, and can
be stored in a freeze-dried (lyophilized) condition requiring only
the addition of the sterile liquid carrier, e.g., water, for
injections immediately prior to use. Extemporaneous injection
suspensions can be prepared from sterile powders, granules, and
tablets of the kind previously described.
[0412] For oral administration, a pharmaceutically acceptable,
non-toxic composition is formed by the incorporation of any of the
normally employed excipients, such as, for example, mannitol,
lactose, starch, magnesium stearate, sodium saccharine, talcum,
cellulose, sodium crosscarmellose, glucose, gelatin, sucrose,
magnesium carbonate, and the like. Such compositions include
suspensions, tablets, dispersible tablets, pills, capsules,
powders, sustained release formulations and the like. Formulations
suitable for oral administration can consists of liquid suspensions
such as effective amounts of the drug encapsulating gagomer
particles suspended in diluents such as water, saline, or orange
juice; sachets, lozenges, and troches, each containing a
predetermined amount of the active ingredient as solids or
granules; powders, suspensions in an appropriate liquid; and
suitable emulsions. Liquid formulations may include diluents such
as water and alcohols, e.g., ethanol, benzyl alcohol, and the
polyethylene alcohols, either with or without the addition of a
pharmaceutically acceptable surfactant, suspending agents, or
emulsifying agents.
[0413] When the composition is a pill or tablet, it will contain,
along with the active ingredient, a diluent such as lactose,
sucrose, dicalcium phosphate, or the like; a lubricant such as
magnesium stearate or the like; and a binder such as starch, gum
acacia, gelatin, polyvinylpyrolidine, cellulose and derivatives
thereof, and the like.
[0414] Tablet forms can include one or more of lactose, sucrose,
mannitol, corn starch, potato starch, alginic acid,
microcrystalline cellulose, acacia, gelatin, guar gum, colloidal
silicon dioxide, crosscarmellose sodium, talc, magnesium stearate,
calcium stearate, zinc stearate, stearic acid, preservatives,
flavoring agents, pharmaceutically acceptable disintegrating
agents, moistening agents, and pharmacologically compatible
carriers.
[0415] Capsule forms can be of the ordinary hard- or soft-shelled
gelatin type containing, for example, surfactants, lubricant, and
inert fillers, such as lactose, sucrose, calcium phosphate, and
corn starch.
[0416] Lozenge forms can contain the drug encapsulating gagomer
particles in a carrier, usually sucrose and acacia or tragacanth,
as well as pastilles comprising the active ingredient in an inert
base such as gelatin or glycerin, or sucrose and acacia.
[0417] The amount of the active ingredient in the pharmaceutical
composition of the present invention to be administered to any
given patient must be determined empirically, and will differ
depending upon the condition of the patients. Relatively small
amounts of the pharmaceutical composition can be administered at
first, with steadily increasing dosages if no adverse effects are
noted. Of course, the maximum safe toxicity dosage as determined in
routine animal toxicity tests should never be exceeded.
[0418] Pharmaceutical compositions within the scope of the present
invention include all compositions wherein the active ingredient is
contained in an amount effective to achieve its intended purpose.
While individual needs vary, determination of optimal ranges of
effective amounts of each compound is within the skill of the art.
The dosage administered will depend upon the age, health, and
weight of the individual recipient thereof as well as upon the
nature of any concurrent treatment and the effect desired. Typical
dosages include 0.01 to 100 mg/kg body weight. The preferred
dosages are in the range of about 0.1 to 100 mg/kg body weight. The
most preferred dosages are in the range of about 1 to 50 mg/kg body
weight.
EXAMPLE 1
Preparation of Polymer-conjugated Lipids (Po-Ls)
[0419] Hyaluronic Acid-conjugated di-palmitoyl
phosphatidylethanolamine (HyPE)
[0420] 20.0 g Hyaluronic Acid was dissolved in 770 ml of the 0.1 M
MES buffer (adjusted with 5N NaOH to pH=6.4) while stirring and
heating to 35.degree. C. (Solution 1). 2.00 g of di-palmitoyl
phosphatidylethanolamine (DPPE) was dissolved in a mixture of 750
ml tert-butanol (93% t-BuOH, 7% water) and 65 ml of water while
stirring and heating to 50.degree. C. until complete dissolution of
the DPPE was achieved (Solution 2).
[0421] Solution 2 was added to Solution 1 under stirring, 2.00 g
HOBT was added and the mixture was allowed to cool to
30.+-.5.degree. C. 20 g EDAC was added and when dissolved (1-2
minutes) the reaction mixture was transferred to a 2 liter RB
flask.
[0422] The reaction mixture was sonicated in an ultrasound bath for
3 hours. On completion of the sonication step, the reaction mixture
was kept stirring overnight at room temperature.
Haemaccel-Conjugated di-palmitoyl phosphatidylethanolamine
(HemPE)
Hem NH Preparation
[0423] 4 g Hexanediamine was dissolved in 400 ml H.sub.2O and then
titrated with HCl to pH=6.0. 500 ml of 3.5% Haemaccel and 2 g EDAC
was added. The pH was maintained at 6.0 for 3-4 h by titration and
the reaction was left overnight. The pH was adjusted the following
morning to 6.0, 0.5 g EDAC was added, and the reaction was
continued for 4 h. The solution was acidified to pH 3.0-4.0 and
filtered through a 10 kD Filtron.
Binding of Hem-NH to Glutaryl-PE (Glu-PE)
[0424] 200 mg Glu-PE was dissolved in C/M:1/1, and the solution was
activated with 800 mg DCC for 1.5 h. The solvents were evaporated
in a rotor vacuum. A solution of 1 g Hem-Nh dissolved in 40 ml
H.sub.2O containing 1 ml DiDAB and 0.5 ml Triethylamine was
immediately added. The reaction was allowed to proceed for 48 h.
The resulting solution was washed with DCM/MeOH/EtOH to remove free
Glu-PE. The aqueous phase was dialysed against water and
lyophilized. Dissolved in H.sub.2O/MeOH:1/1, passed through an ion
exchange column (Amberlite IR 120). Dialysed against water,
lyophilized.
Preparation of the Liposomes
[0425] Unilamellar liposomes were prepared from lipids, such as
DMPC or egg-PC with/without 33 mole % cholesterol, dissolved in
tert-butanol, were lyophilized to dryness, suspended in
tris-buffer, pH=7.4, and subjected to extrusion through a
polycarbonate filter, to obtain nano-liposomes sized between 50-100
nm average diameter, according to a published procedure (MacDonald
et al., 1991). To obtain Po-L/lipid liposomes, the lipid
suspensions were mixed with Po-L solutions (e.g., HyPE or Hem-PE in
buffer) at the desired ratio, prior to extrusion. The size of the
mixed nano-liposomes was determined by dynamic light
scattering.
Results
[0426] Po-L/Lipid form nano-liposomes of 100-130 nm, suitable for
selective penetration of the inter-cellular space of inflamed
tissues, while avoiding penetration into healthy tissues, with a
packing parameter of 0.8 (stable range=0.74-1.0). FIG. 2 shows the
mole percent of PE conjugated to HyPE in the liposomes needed to
obtain optimal stability for PE-HyPE liposomes, which is obtained
when the packing parameter (PP) is close to 1.0 (but not higher
than 1).
[0427] The size of Po-L/Lipid nanoliposomes was stable at
60.degree. C. for at least 27 days (data not shown), while the size
of bare lipid dimyristoyl phosphatidyl-choline (DMPC) nanoliposomes
(control) increased by day 17 (FIG. 3) and began decreasing at day
20 (data not shown). Nanoliposomes comprising 1.6% HyPE-2, 0.6%
HyPE-5, Dex(5)-PE, Dex(40)-PE, Heta-PE, and Hem-PE all had more
stable nanoliposome size than control nanoliposomes (FIG. 3).
HyPE-2 and HyPE-5 describe the molar ratio of hyaluronic acid to PE
in those conjugates, which can also be described as the number of
hyaluronic acid disaccharide units per PE (Table 2).
TABLE-US-00002 TABLE 2 Composition of two HyPE batches, tested for
their effect on the size stability of Po-L-containing DMPC
liposomes (as in FIG. 3). Batch of PE/HA* **DSU/PE HyPE (mol/mol)
(mole/mole) HyPE-2 2-3 62 HyPE-5 5 28 *HA Average MW = 50 KD; **DSU
= HA Disaccharide Units (MW = 379) in HyPE
[0428] Po-L/Lipid NL were markedly more resistant lysis by external
phospholipase A2 (the major PL-hydrolyzing enzyme) than control
(FIG. 4) or PEGylated (data not shown) nanoliposomes. In addition,
the release of encapsulated drug from Po-L/Lipid nanoliposomes (2
days in plasma, 37.degree. C.) was significantly slower than from
control nanoliposomes in both in vitro (FIG. 5) and in vivo (FIG.
6) experiments.
[0429] These results suggest that Po-L/Lipid NL are suitable for
slow release and targeted delivery of drugs, and may have
advantages over currently used compositions: Some PoSPL have been
developed as anti-inflammatory drugs, and their use thus provides
an additional therapeutic benefit, and are composed of natural
biodegradable non-immunogenic and non-toxic, as documented in
numerous previous studies. In addition, the Po-L provide a platform
of compositions that can be modified to be used for differential
treatments and organ targeting.
[0430] While certain features of the invention have been
illustrated and described herein, many modifications,
substitutions, changes, and equivalents will now occur to those of
ordinary skill in the art. It is, therefore, to be understood that
the appended claims are intended to cover all such modifications
and changes as fall within the true spirit of the invention.
* * * * *